EFFECTS OF INHIBITING THE MAMMALIAN TARGET OF RAPAMYCIN (MTOR) PATHWAY AND TELOMERASE IN BREAST CANCER CELLS by GOPALAKRISHNAN KALPANA
 EFFECTS OF INHIBITING THE MAMMALIAN 
TARGET OF RAPAMYCIN (mTOR) PATHWAY AND 













A THESIS SUBMITTED 
 
FOR THE DEGREE OF MASTER OF SCIENCE 
 
DEPARTMENT OF PHYSIOLOGY 
 






I take this opportunity to extend my heartfelt gratitude to all those without 
whom this Masters thesis would not have been possible. First and foremost, I would 
like to thank my supervisor A/P Manoor Prakash Hande for all the guidance, support 
and inspiration offered to me during my course of research under him. I am also 
grateful for all the valuable advice and encouragement extended by him to me in the 
context of research and beyond. I especially would also like to thank him for having 
given me the opportunity to attend a number of quality conferences, both international 
and local.  
 The friendships nurtured at Genome Stability Lab, helped to make the work in 
this thesis both educative and enjoyable. I would like to extend my gratitude to all lab 
members who provided timely assistance and encouragement throughout. 
 Last but not the least I would like to express my appreciation to members of 
other labs in the Department of Physiology who have helped me with advice on 









TABLE OF CONTENTS 
 
ACKNOWLEDGEMENTS......................................................................i 
TABLE OF CONTENTS.........................................................................ii 
SUMMARY............................................................................................viii 
LIST OF FIGURES..................................................................................x 
LIST OF ABBREVIATIONS...............................................................xiii 
 
CHAPTER 1 INTRODUCTION.............................................................1 
1.1 THE MAMMALIAN TARGET OF RAPAMYCIN (mTOR): STRUCTURE, 
FUNCTION AND ROLES IN CANCER...................................................................2 
1.1.1 The role of mTOR in cell physiology...................................................................2 
1.1.2 mTOR pathway: upstream regulators of mTOR signalling..................................4 
1.1.3 mTOR in human cancer........................................................................................6 
1.2 TELOMERES AND TELOMERASE: STRUCTURE, FUNCTION AND 
ROLES IN CANCER.................................................................................................11 
1.2.1 Telomeres: Structure and functions.....................................................................11 
1.2.2 Telomere related functions of telomerase in human cancer................................13 
iii 
 
1.2.3 Expanding telomerase functions in human cancer..............................................15 
1.2.4 Regulation of telomerase activity in human cancer............................................17 
1.3 LINKING mTOR AND TELOMERASE THROUGH RAPAMYCIN..........19 
1.3.1 Rapamycin as an inhibitor of mTOR..................................................................19 
1.3.2 The mTOR-telomerase connection via rapamycin..............................................22 
1.3.3 The convergence of the mTOR pathway with telomeres and telomerase...........24 
1.4 BREAST CANCER AS A MODEL OF STUDY...............................................25 
1.4.1 mTOR in breast cancer........................................................................................25 
1.4.2 Telomerase in breast cancer................................................................................26 
1.4.3 Rapamycin in breast cancer.................................................................................27 
1.5 OBJECTIVES, HYPOTHESIS AND SIGNIFICANCE OF STUDY.............29 
 
CHAPTER 2 MATERIALS AND METHODS...................................31 
2.1 CELLS AND CELL CULTURE.........................................................................32 
2.2 MOLECULAR CHARACTERISATION OF BREAST CANCER CELLS..33 
2.3 DRUG AND DRUG TREATMENT CONDITIONS........................................33 
2.4 SHORT TERM STUDIES...................................................................................34 
2.4.1 Cell treatment......................................................................................................34 
2.4.2 Protein expression studies by western blot..........................................................35 
iv 
 
2.4.3 Telomerase activity measurement by Telomerase Repeat Amplification Protocol 
(TRAP).........................................................................................................................37 
2.4.4 Cell Cycle profiling by Propidium Iodide (PI)-assisted Fluorescence Associated 
Cell Sorting (FACS).....................................................................................................38 
2.4.5 DNA damage analysis by alkaline single cell gel electrophoresis (Comet) 
assay.............................................................................................................................39 
2.4.6 Cell Viability.......................................................................................................40 
2.4.6.1 MTT..................................................................................................................40 
2.4.6.2 CellTiter-Glo....................................................................................................40 
2.5 LONG TERM STUDIES.....................................................................................41 
2.5.1 Cell Treatment.....................................................................................................41 
2.5.2 Population doubling via Trypan blue dye exclusion assay.................................42 
2.5.3 Telomere length measurement by Telomere Restriction Fragment (TRF) 
analysis.........................................................................................................................42 
2.6 STATISTICAL ANALYSIS................................................................................44 
CHAPTER 3 RESULTS........................................................................45 
3.1 MOLECULAR CHARACTERIZATION OF BREAST CANCER CELLS..46 
3.1.1 Breast cancer cells MCF-7 and MDA-MB-231 exhibited concurrent 




3.2 RAPAMYCIN CHARACTERIZATION: SHORT TERM STUDIES...........50 
3.2.1 Rapamycin inhibited activation of mTOR pathway in MCF-7 and MDA-MB-
231 cells………………................................................................................................50 
3.2.2 Rapamycin did not modulate hTERT protein, but inhibited telomerase activity in 
MCF-7 and MDA-MB-31 cells, albeit to different extents..........................................53 
3.2.3 Rapamycin induced G1 arrest in MCF-7 and MDA-MB-231 cells at 24 and 48 
hours.............................................................................................................................55 
3.2.4 Rapamycin-induced G1 arrest was independent of cyclin D1 and p21 protein 
expression.....................................................................................................................57 
3.2.5 Rapamycin had limited effect on cell proliferation following 48 hours in MCF-7 
and MDA-MB-231 cells...............................................................................................58 
3.2.6 Rapamycin had limited effect on DNA damage following 48 hours in MCF-7 
and MDA-MB-231 cells...............................................................................................59 
3.2.7 Rapamycin led to dose-dependent loss of viability in MCF-10A and IMR-90 
cells...............................................................................................................................60 
3.3 RAPAMYCIN THERAPEUTICS: LONG TERM STUDIES.........................62 
3.3.1 Rationale..............................................................................................................62 
3.3.2 Chronic rapamycin treatment compromised population doubling capacity of 
MCF-7, MDA-MB-231 and MCF-10A cells, albeit to different extents.....................63 
3.3.3 Chronic rapamycin treatment inhibited the mTOR pathway in MCF-7 and 
MDA-MB-231 cells, and led to upregulation of p-Akt in MDA-MB-231 cells..........65 
vi 
 
3.3.4 Chronic rapamycin treatment led to slight downregulation of hTERT protein in 
MCF-7 and MDA-MB-231 cells, with a slight decrease and increase in telomerase 
activity in MCF-7 and MDA-MB-231 cells, respectively...........................................66 
3.3.5 Chronic rapamycin treatment led to reduction of telomere length in MCF-7 and 
MDA-MB-231 cells, albeit to different extents...........................................................68 
 
CHAPTER 4 DISCUSSION..................................................................71 
4.1 BREAST CANCER CELLS MCF-7 AND MDA-MB-231 ARE A GOOD 
MODEL TO STUDY THE INHIBITION OF mTOR AND TELOMERASE.....72 
4.2 UPREGULATION OF P-MTOR AND TELOMERASE DOES NOT 
NECESSARILY PREDICT RESPONSIVENESS TO RAPAMYCIN.................75 
4.3 CHRONIC LOW DOSE RAPAMYCIN TREATMENT IN BREAST 
CANCER CELLS REVEALS A NOVEL MECHANISM OF RAPAMYCIN 
RESISTANCE INVOLVING AKT AND TELOMERASE...................................80 
CHAPTER 5 CONCLUSIONS, SIGNIFICANCE AND FUTURE 
DIRECTIONS.........................................................................................84 
5.1 CONCLUSIONS AND SIGNIFICANCE..........................................................85 





LIST OF CONFERENCES.................................................................101 
LIST OF PUBLICATIONS.................................................................102 





 This investigation explores the effects of rapamycin on the mTOR pathway 
and telomerase in breast cancer cells.  
The mTOR pathway, a prototypic survival pathway upregulated in many 
cancers, integrates various cellular signals serving as a master regulator of protein 
synthesis, ribosome biogenesis, autophagy, survival and proliferation. It also plays a 
major role in drug resistance, making mTOR an attractive anticancer target. The 
telomerase enzyme maintains telomere length, allowing cells to bypass the anti-
proliferative barriers of senescence and crisis. Telomerase upregulation occurs in 
more than 90% of human cancers in addition to being critical and specific to cancer 
cells, making it another attractive anticancer target.  
The macrolide antibiotic rapamycin inhibits the mTOR pathway specifically 
and potently and exerts anticancer effects in a wide variety of cancers. Recent studies 
also showed that rapamycin inhibited telomerase and induced telomere shortening in 
some malignancies, although the mechanism is poorly understood.  
Breast cancers exhibit aberrant regulation of both the mTOR pathway and 
telomerase and hence may be a useful model to study the effects of rapamycin. Using 
this model, the investigation seeks to unravel novel mechanisms by which breast 
cancer cells may regulate the complex mTOR circuitry and telomerase by as yet 
uncharacterised mechanisms.  
Our results showed that breast cancer cells MCF-7 and MDA-MB-231 
exhibited concurrent upregulation of phosphorylated mTOR (p-mTOR) and hTERT, 
albeit to different extents. In short term studies, we found that rapamycin inhibited 
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activation of the mTOR pathway, did not modulate hTERT protein, but significantly 
inhibited telomerase activity in MCF-7 and MDA-MB-31 cells. Rapamycin induced 
G1 arrest in both cells independently of cyclin D1 and p21 expression. Rapamycin 
had limited effect on cell proliferation and DNA damage in MCF-7 and MDA-MB-
231 cells, and led to dose-dependent loss of viability only in MCF-10A and IMR-90 
cells. Altogether these results suggest that while breast cancer cells may be a useful 
model to study the dual inhibition of the mTOR pathway and telomerase, the 
activation of these two players alone cannot predict the responsiveness of these cells 
to short term rapamycin treatment. 
Long term studies showed that low dose rapamycin treatment compromised 
population doubling capacity of MCF-7, MDA-MB-231 and MCF-10A cells and 
inhibited the mTOR pathway and hTERT protein in MCF-7 and MDA-MB-231 cells. 
MCF-7 cells exhibited a decrease in telomerase activity and a concomitant reduction 
in telomere length. Interestingly, in MDA-MB-231 cells we observed upregulation of 
p-Akt, increase in telomerase activity and no significant change in telomere length. 
These data implicate novel mechanisms other than mTOR, specifically telomerase, in 
mediating the anticancer effects of rapamycin. Further, while rapamycin may function 
as a dual inhibitor of mTOR and telomerase, sustained rapamycin treatment leading to 
Akt activation may play a role in resistance via telomerase activation in some breast 
cancers.  
Altogether, the investigation highlights a novel mode of rapamycin action in 
breast cancer cells and shows that rapamycin may be a useful tool to study the 
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phosphorylate and activate PI3K to produce more of Akt. Overstimulation of Akt may 
lead to enhanced activation of telomerase, and hence continued cell proliferation. This 
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1.1 THE MAMMALIAN TARGET OF RAPAMYCIN (mTOR): 
STRUCTURE, FUNCTIONS AND ROLES IN CANCER 
1.1.1 The role of mTOR in cell physiology 
The mTOR signalling network is an evolutionarily conserved prototypic 
survival pathway of serine/threonine kinases which integrates signals from nutrients 
and growth factors to regulate processes as diverse as protein synthesis, ribosome 
biogenesis, autophagy, cell cycle regulation and angiogenesis, driving cellular growth, 
survival and proliferation. A member of the phosphatidylinositol kinase-related 
protein kinase (PIKK) family, mTOR and other proteins in the pathway are frequently 
misregulated in cancers and are also implicated in drug resistance mechanisms against 
various types of anticancer therapy (LoPiccolo, Blumenthal et al. 2008; Menon and 
Manning 2008).  
The TOR genes, TOR1 and TOR2 were first identified in the budding yeast, 
Saccharomyces cerevisiae, in a genetic screen for mutations conferring resistance to 
rapamycin, a naturally occurring macrolide antibiotic (Heitman, Movva et al. 1991). 
TOR1 and TOR2 exist in two physically and functionally distinct macromolecular 
complexes, TOR complex 1 (TORC1) and TORC2, and conserved from yeast to 
humans (Loewith, Jacinto et al. 2002). In humans, mTORC1 consists of Raptor 
(Regulatory associated protein of mTOR) and mLST8 (mammalian Lethal with 
SEC13 protein 8), and mTORC2 consists of Rictor (Rapamycin insensitive 
companion of mTOR), mSIN1 (mammalian Stress-activated protein kinase interacting 
protein 1) and mLST8 (Hara, Maruki et al. 2002; Kim, Sarbassov et al. 2002; 
Loewith, Jacinto et al. 2002; Kim, Sarbassov et al. 2003; Jacinto, Loewith et al. 2004; 
Sarbassov, Ali et al. 2004; Jacinto, Facchinetti et al. 2006; Yang, Inoki et al. 2006).  
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The two complexes are not only distinguished by their sensitivity to 
rapamycin, but also by their diverse downstream effectors. Rapamycin treatment 
acutely inhibits mTOR within mTORC1, but not mTORC2, although prolonged 
treatment can block mTORC2 assembly resulting from rapamycin-induced 
sequestration of mTOR in mTORC1 (Sarbassov, Ali et al. 2006).  
In response to stimuli such as growth factors and nutrients, mTORC1 is 
activated and controls cell growth by stimulating protein synthesis via two major 
downstream effectors: the ribosomal S6 kinases (S6K1 and S6K2) and the eukaryotic 
initiation factor 4E (eIF4E)-binding proteins (4E-BP1) (Menon and Manning 2008). 
On phosphorylation and activation by mTORC1, S6K1 phosphorylates the 40S 
ribosomal protein S6, which in turn enhances the translation of mRNAs with a 5‟ 
terminal oligopyrimidine tract, such as elongation factor-1α and ribosomal proteins 
(Jefferies, Fumagalli et al. 1997). Once phosphorylated by mTORC1, 4E-BP1 
dissociates from eIF4E; free eIF4E leads to enhanced cap-dependent translation 
initiation, especially of mRNAs with long, highly structured 5‟-untranslated regions, 
such as cyclin D1 and c-myc,  which are important regulators of cell cycle entry 
(Clemens and Bommer 1999; Dufner, Andjelkovic et al. 1999; Gera, Mellinghoff et 
al. 2004).  
The upstream molecular events governing mTORC2 activation are poorly 
understood, while the downstream functions of mTORC2 have been relatively better 
elucidated and involve control of actin cytoskeleton and cell polarity (Sarbassov, Ali 
et al. 2004). The most well characterized substrate of mTORC2 is Akt, whereby it 
phosphorylates Akt at S473, leading to its full activation (Sarbassov, Guertin et al. 
2005). mTORC2 also phosphorylates protein kinase C-α (PKC-α) and serum 
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glucocorticoid-induced kinase 1 (SGK1) (Sarbassov, Ali et al. 2004; Guertin, Stevens 
et al. 2006; Garcia-Martinez and Alessi 2008).  
 
1.1.2 mTOR pathway: upstream regulators of mTOR signalling  
 Because the upstream modulators of mTORC2 remain inadequately 
elucidated, the following discussion will pertain to the much better understood 
regulators of mTORC1.  
 mTORC1 functions mainly to control protein synthesis. The protein synthetic 
capacity of a eukaryotic cell profoundly impacts on fundamental controls on cell 
growth, proliferation and survival. Hence upstream regulators of mTORC1 are 
exquisite mechanisms that the cell has evolved to sense cellular growth conditions 
such as nutrient and energy levels and secreted growth factors. Most ligand/growth 
factor receptor interactions activate mTOR through the activation of two major 
sources: Phosphatidylinositol-3-kinase (PI3K), an important signalling module 
downstream of receptor tyrosine kinases (RTKs) and oncogenic Ras, and the AMP-
activated protein kinase (AMPK), a master sensor of cellular energy supply. (Cantley 
2002; Hardie, Scott et al. 2003; Sehgal 2003; Alessi, Sakamoto et al. 2006).  
 PI3K phosphorylates phosphatidylinositol lipids at the D-3 position to 3‟-
phosphoinositides, which activate both Akt and phosphoinositide-dependent kinase-1 
(PDK-1). Phosphatase and tensin homolog (PTEN) opposes the function of PI3K by 
removing 3‟-phosphate groups. Akt activates mTOR directly by phosphorylation at 
S2448 or indirectly, by phosphorylation and inactivation of the tuberous sclerosis 
complex 1-2 (TSC1-TSC2) protein complex. When the TSC1-TSC2 complex is 
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inactivated, the GTPase Ras homolog enriched in brain (Rheb) is maintained in its 
GTP-bound state, allowing for increased activation of mTORC1 (LoPiccolo, 
Blumenthal et al. 2008). In fact many of the cellular pathways that affect mTORC1 do 
so by TSC1-TSC2 inactivation (Menon and Manning 2008).  mTORC1 can be further 
stimulated by Akt-mediated phosphorylation of Proline-rich Akt substrate of 40 kDa 
(PRAS40), which is a subunit of mTORC1 not necessary for its core complex 
function (Sancak, Thoreen et al. 2007; Vander Haar, Lee et al. 2007). The fact that 
Akt can regulate mTORC1 in three different ways strongly places mTORC1 
activation by growth factor receptor signalling downstream of Akt. Interestingly, the 
ability of mTORC2 to activate Akt provides a mechanism by which mTORC1 and 
mTORC2 may regulate reach other. Other characterised modes of mTORC1 
activation include ribosomal S6 kinase-mediated phosphorylation of Raptor (Carriere, 
Cargnello et al. 2008).  
 Under conditions of energy depletion, the highly conserved energy sensing 
protein AMPK is activated and phosphorylates TSC2, which shuts down mTORC1 
activity by inhibiting Rheb (Inoki, Zhu et al. 2003; Shaw, Bardeesy et al. 2004). 
Additionally, AMPK directly inhibits mTORC1 by phosphorylating specific sites on 
Raptor (Gwinn, Shackelford et al. 2008). In this way the cell uses the mTOR pathway 








1.1.3 mTOR in human cancer 
Malignant transformation is proposed to be dictated by eight essential 
alterations in cell physiology: self-sufficiency in growth signals, insensitivity to 
growth-inhibitory signals, evasion of apoptosis, limitless replicative potential, 
sustained angiogenesis, tissue invasion and metastasis, reprogramming of cellular 
                                                          
1
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metabolism and evasion of immune destruction (Hanahan and Weinberg 2011). 
Aberrant activation of mTOR appears to drive tumourigenesis and tumour progression 
by altering each of these features leading to uncontrolled cell growth, proliferation 
and survival of cancer cells.   
The signalling system that relays information from the outside of the cell 
towards mTORC1 constitutes central tumour suppressors and oncogenes, the 
misregulation of which has been implicated in many human tumours. Consequently, 
the observation of upregulated mTORC1 activity in most human cancers is hardly 
surprising.  
The biomarkers of mTORC1 activation are scored by investigating the relative 
phosphorylation levels of its direct downstream targets 4E-BP1, S6K1 and ribosomal 
S6. In general, phosphorylation of S6K1 on T389, S6 on 240/244 and 4E-BP1 on S65 
are quite specific and critical to mTORC1 signalling (Menon and Manning 2008). 
Although phosphorylation of mTORC1 on S2448 indicates its activation, this site is 
also found to be phosphorylated in mTORC2 (Rosner, Siegel et al. 2010).  
Constitutive activation of PI3K/Akt and extra cellular signal regulated kinase 
(ERK) signalling pathways are perhaps the two most common oncogenic events 
leading to aberrant mTORC1 activation (Engelman, Luo et al. 2006; Shaw and 
Cantley 2006; Roberts and Der 2007). Gene mutations and amplifications leading to 
ligand-independent signalling from upstream RTKs, scaffolding adaptors and 
oncogenic Ras are the most common activators feeding into both of these crucial 
signalling pathways. Additionally, loss of PTEN occurs in most human cancers and 
leads to activation of Akt, which impacts on mTORC1 (Menon and Manning 2008).  
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As we have already seen, AMPK is a critical mediator of cellular energy 
levels. Liver kinase B1 (LKB1) is a critical tumour suppressor and upstream activator 
of AMPK. Loss of LKB1 occurs frequently in cancers such as non-small-cell lung 
cancer, allowing cancer cells to become insensitive to intracellular energy levels and 
continue to survive under conditions of energy depletion, by activating mTORC1 
(Shaw 2009).  
Although the role of mTORC1 in apoptosis remains poorly elucidated, studies 
have shown that mTORC1 activates the translation of pro-survival members 
belonging to the Bcl-2 family and the anti-apoptotic protein FLIPs (Panner, James et 
al. 2005; Mills, Hippo et al. 2008).  
As previously discussed, mTORC1 activation leads to the cap-dependent 
translation initiation of mRNAs that encode for proteins such as cyclin D1 and c-myc, 
which drive cell cycle entry and progression (Gera, Mellinghoff et al. 2004). Akt also 
feeds into this process by downregulating cell cycle inhibitors p27 and p21, leading to 
increased cyclin D1 and c-myc (Di Cosimo and Baselga 2008). Additionally, myc has 
been shown to directly repress TSC2 expression, providing a possible feedback 
mechanism by which mTORC1 may maintain its activity (Schmidt, Ravitz et al. 
2009). While cyclin D1 promotes cell cycle entry from the G1 to the S phase, the 
implications of c-myc upregulation are more far reaching; the c-myc gene has been 
reported to modulate the expression of more than 3000 genes. Of relevance, c-myc is 
a direct transcriptional activator of hTERT, the catalytic subunit of the telomerase 
complex, which is critical and specific in conferring cancer cells with unlimited 
replicative potential (Wang, Xie et al. 1998; Harley 2008; Dimri 2009). This notion 
will be discussed in further detail in the subsequent section (1.2).  
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mTORC1 has been shown to increase the translation of hypoxia-inducible 
factor-1α (HIF-1α), leading not only to increased glucose uptake into tumours, but 
also increased levels of vascular endothelial growth factor A (VEGF-α). These 
directly implicate mTORC1 in metabolic reprogramming and angiogenesis in tumour 
cells (Menon and Manning 2008).   
The role for mTORC2 in cancer cell survival and proliferation is only now 
slowly beginning to be unravelled. A recent study by Kim et al. revealed that 
mTORC2 selectively activates Akt1, and in doing so, regulates cancer cell migration, 
invasion and metastasis (Kim, Yun et al. 2011).  
 Studies have shown that the mTOR pathway is commonly activated in a 
diverse array of human tumours. The selective advantage gained by mTOR activation 
in cancer cells and the increasing knowledge on the implications of mTOR in 
promoting and maintaining malignant transformation have placed mTOR as a critical 
anticancer therapeutic target. Ongoing clinical trials are testing the efficacy of 
rapamycin and its analogues, cell cycle inhibitor (CCI)-779 and RAD001 against 
nearly all major forms of cancers. Because rapamycin and its analogues are all 
allosteric inhibitors, they block only a subset of mTORC1 function, and as mTORC2 
is also now being more implicated in carcinogenesis, it is valuable to test the efficacy 
of mTOR kinase domain inhibitors in preclinical and clinical studies (Menon and 
Manning 2008). These will be discussed in detail in the context of rapamycin‟s status 








1.2 TELOMERES AND TELOMERASE: STRUCTURE, 
FUNCTIONS AND ROLES IN CANCER 
1.2.1 Telomeres: Structure and functions 
 Linear eukaryotic chromosomes end in highly specialised nucleoprotein 
structures called telomeres, an organised combination of tandem non-coding repeats 
of TTAGGG sequences and telomere-associated proteins (Blackburn, Greider et al. 
2006). They cap chromosome ends, preserving genome stability by preventing the 
fusion of exposed chromosome ends. Additionally, progressive telomere shortening 
with each cell division confers cells with limited proliferative capacity, allowing 
telomeres to modulate cellular lifespan (Harley, Futcher et al. 1990; Levy, Allsopp et 
al. 1992; Rodier, Kim et al. 2005).  
 Double stranded telomeric repeats can vary in length between 50 to 200 
kilobase pairs and end in a short single-stranded G-rich 3‟-overhangs, or G-tails. In 
mammalian cells, G-tails turn back into the duplex portion of the telomere to form an 
additional t-loop, which is stabilised by associating with a six-subunit protein 
complex, or shelterin, comprising TRF1, TRF2, TIN2, Rap1, TPP1, and POT1. This 
complex between telomeric DNA and telomere-associated proteins serves to form the 
„cap‟ that safeguards genome stability (Osterhage and Friedman 2009). 
 Cells in culture exhibit a limited capacity for population doublings, due to the 
end replication problem, an inherent inability for the eukaryotic DNA replication 
machinery to fully replicate to the end of a duplex DNA (Hayflick and Moorhead 
1961; Watson 1972; Olovnikov 1973). Consequently, telomeres shorten with each cell 
division, acting as a buffer to circumvent the loss of critical DNA from gene encoding 
regions. When telomeres shorten to a critical length after a characteristic number of 
12 
 
cell divisions, they trigger a DNA damage checkpoint response, leading to replicative 
senescence (Shay and Wright 2005). Cell cycle checkpoint activities involving p53, 
p21, pRB and ataxia telengiectasia mutated (ATM) play critical roles in initiation and 
maintenance of the senescence state (Herbig, Jobling et al. 2004). Cells that lose these 
critical cell cycle checkpoint functions escape the initial growth arrest and continue to 
divide until they reach a second growth arrest state called crisis. This state is 
characterised by chromosome end fusions due to telomere dysfunction, leading to 
chromosome bridge-breakage-fusion cycles, and almost always lead to apoptosis. 
Indeed replicative senescence and crisis are two critical telomere-dependent pathways 
of cellular mortality that are exploited by cancer cells to achieve unlimited 
proliferative capacity. This is mostly achieved by the upregulation of the enzyme 
telomerase or by an alternative recombination-based telomere maintenance (ALT) 
mechanism. (Cheung and Deng 2008; Zou, Misri et al. 2009).  
 
Figure 3. A. Chromosome end maintenance by telomeres and telomere-associated 
proteins that form D- and T-loops, B. Telomere-associated proteins and telomerase at 






1.2.2 Telomere-related functions of telomerase in human cancer 
 When cells in crisis do not undergo apoptosis, they can continue to divide by 
expressing the telomerase enzyme. It is now becoming increasingly clear that 
telomerase activation necessarily occurs post rampant chromosomal instability at 
crisis, so as to stabilise the genome and confer unlimited proliferative capacity upon 
the evolving cancer cell. Consequently, cellular immortalization conferred by 
telomerase is generally regarded as a critical step in cancer progression. Indeed cells 
that have escaped crisis have two defining hallmarks: reactivation of telomerase and 
telomere stability conferred by telomerase‟s role in preserving structural integrity at 
the chromosome ends (Kim, Piatyszek et al. 1994; Shay and Bacchetti 1997). By 
extending telomeric DNA, telomerase counters the progressive telomere erosion that 
would otherwise occur in its absence. This role of telomerase at telomeres is regarded 
as its classical or canonical function.  
 The telomerase ribonucleoprotein enzyme is composed of a minimal catalytic 
core, which includes the telomerase reverse transcriptase (TERT) protein and the 
telomerase RNA component (TERC). TERC functions as the template for TERT to 
add telomere repeats in a reverse transcriptase reaction at the chromosome end 
(Blackburn, Greider et al. 2006).  
Cellular immortalization by telomerase is now regarded a cancer hallmark, 
and telomerase is recognised as the most promising anticancer target to date, for its 
universality, criticality and specificity to tumour cells (Harley 2008; Hanahan and 
Weinberg 2011). Telomerase activation appears to be present in up to 90% of all 
human cancers, making it the most widely expressed tumour trait. The fact that 
telomerase is encoded by non-redundant genes, has implications in therapeutic 
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resistance, which normally appears as a consequence of targeting a protein that is a 
member of a family of genes such as growth factor receptors or signal transduction 
enzymes. Furthermore, it is specific to cancer cells and not normal cells (Kim, 
Piatyszek et al. 1994; Harley 2008). Telomerase is active in certain germ line cells 
and in early human embryogenesis, but is repressed upon tissue differentiation during 
development (Wright, Piatyszek et al. 1996). Hence, most human somatic cells are 
devoid of telomerase activity after birth. Thus, although telomerase itself is not an 
oncogene, telomerase repression and tight regulation in humans appears to be a 
tumour suppressor mechanism, at least early in life (Harley 2008). For instance, low 
levels of telomerase activity that are insufficient to prevent telomere shortening with 
age, do continue to be expressed, at least transiently in normal stem cells as well as 
proliferative tissues such as breast epithelial cells, endometrial tissues, the basal layer 
of the skin including hair follicles and intestinal crypt cells (Greider 1998; Holt and 
Shay 1999; Collins and Mitchell 2002). Finally, tumour cells have been found to have 
significantly shorter telomeres than normal human somatic cells owing to the late 
activation of telomerase or to their extensive replicative history without sufficient 
telomerase to maintain telomere length, or both. Whatever the case may be, the 
delayed acquisition of telomerase serves to generate tumour-promoting mutations, 
while its subsequent activation stabilizes the mutant genome and confers the 
unlimited replicative capacity that cancer cells require in order to generate clinically 
apparent tumours. Compounded by the fact that tumour cells are more proliferative 
than stem cells that express telomerase, the difference in telomere lengths provides a 
degree of tumour specificity to telomerase-based drugs and reduces the probability of 




1.2.3 Expanding telomerase functions in human cancer 
 The strict relationship between telomere length and replicative senescence on 
the one hand and telomerase expression and cellular immortality on the other hand 
was highlighted by experiments that demonstrated that ectopic expression of the 
human TERT (hTERT) cDNA is sufficient to give rise to telomerase activity and 
confers cells with indefinite proliferative potential (Bodnar, Ouellette et al. 1998). 
However, the hypothesis that telomerase may have a role in tumour progression 
beyond telomeres came from early observations whereby mouse models of epidermal 
or mammary carcinogenesis exhibited enhanced telomerase activity despite the 
massive telomere reserves in these cells (Bednarek, Budunova et al. 1995; Chadeneau, 
Siegel et al. 1995; Broccoli, Godley et al. 1996). Regarded as non-canonical functions 
of telomerase, this hypothesis can be further supported by recent evidence that TERT 
can be found associated with chromatin at multiple sites along the chromosomes and 
not just at the telomeres (Masutomi, Possemato et al. 2005; Park, Venteicher et al. 
2009).  
 Non-canonical functions of telomerase involve correct response to DNA 
damage, the induction of neoplasia in both epidermis and mammary gland, and 
insensitivity to transforming growth factor β (TGF-β) (Parkinson, Fitchett et al. 2008). 
Independent of its role in telomere stabilization, TERT appears to preserve genome 
stability by modulating DNA damage response signalling via ATM, breast cancer 
gene 1 (BRCA1) and gamma-H2AX, as well as histone and heterochromatin 
modifications (Masutomi, Possemato et al. 2005). This appears counterintuitive in the 
wake of the recognition that genome instability is a hallmark of cancer (Hanahan and 
Weinberg 2011). However, TERT appears to confer genome stability to levels that 
seem sufficient for continued cellular proliferation, which is supported by the 
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observation that there is a quelling of genomic instability consistent with telomerase 
activation, with cancer progression (Artandi and DePinho 2010).  
An analysis of human mammary epithelial cells transduced with hTERT 
showed upregulation of growth promoting genes and downregulation of growth 
inhibitory genes, in addition to correlating with decreased need for mitogens (Smith, 
Coller et al. 2003). Studies have also shown that telomerase inhibition results in cell 
growth arrest and induction of apoptosis independent of telomere length reduction, 
and is associated with a concomitant reduction in transcription of genes involved in 
cell cycle progression, tumour growth, angiogenesis and metastasis (Li, Rosenberg et 
al. 2004; Li, Crothers et al. 2005). Conversely, overexpression of hTERT rendered 
cells more resistant to apoptosis (Gorbunova, Seluanov et al. 2002; Zhang, Chan et al. 
2003). Telomerase has recently been found to alter the energy state of tumour cells by 
regulating metabolic pathways such as glycolysis (Bagheri, Nosrati et al. 2006). 
Furthermore, telomerase induction has been associated with enhanced DNA repair 
and genomic stability, while inhibition of telomerase has been associated with 
increased sensitivity to ionising radiation and reduced repair of DNA double strand 
breaks (Sharma, Gupta et al. 2003; Masutomi, Possemato et al. 2005). Long term 
proliferation of telomerase-immortalised cells has been associated with events critical 
for tumour progression such as overexpression of oncogenes such as myc, 
upregulation of cell cycle regulators such as cyclin D1, resistance to growth inhibition 
induced by TGF-β, loss of p53 function and p14ARF expression (Jagadeesh and 
Banerjee 2006). Telomerase may further play a protective role against damaging 
agents and stressful conditions and prevent apoptosis (Mondello and Scovassi 2004; 




1.2.4 Regulation of telomerase activity in human cancer 
Gene amplification, alternative splicing, and changes in subcellular 
localization and phosphorylation are just some of the proposed modulators of 
telomerase expression and activity in the context of human cancers (Aisner, Wright et 
al. 2002). Several oncogenes and oncogenic pathways have also been shown to 
regulate telomerase activity, possibly indicating that telomerase activity could be 
downstream to various oncogenic events that enable cancer cells to proliferate 
indefinitely in the presence of mutations.  
At the transcriptional level, the oncogene c-myc was found to positively 
regulate the hTERT gene (Wang, Xie et al. 1998). Other cellular transcriptional 
activators such as Sp1, HIF-1, AP2, estrogen receptor (ER) and Ets have also been 
identified to regulate the hTERT promoter in cancers. Additionally, the hTERT 
promoter is modulated by chromatin structure rearrangements such as DNA 
methylation and regulation of nucleosome histones (Kyo, Takakura et al. 2008). 
Furthermore, three prominent oncoproteins, human epidermal growth factor receptor 
(HER2), Ras, and Raf, facilitate hTERT expression in hTERT-negative normal cells 
(Goueli and Janknecht 2004). 
Akt has been shown to enhance telomerase activity by phosphorylating TERT 
(Kang, Kwon et al. 1999). Also, telomerase activity is enhanced by growth factors 
such as insulin-like growth factor 1 (IGF-1), fibroblast growth factor 2 (FGF2), 
vascular endothelial growth factor (VEGF) and epidermal growth factor (EGF), and 
also by interleukins, all of which are implicated in tumour initiation and progression 
(Liu, Chen et al. 2010).  
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Proteins such as TPP1 which indirectly regulate telomerase by recruiting it to 
telomeres are also now being considered possible anticancer targets (Tejera, Stagno 
d'Alcontres et al. 2010).  
 Because telomerase is fast becoming an attractive anticancer target, several 
different approaches are being explored to inhibit it: drugs that inhibit telomerase 
enzymatic activity, active immunotherapy, gene therapy using telomerase promoter-
driven expression of a suicide gene, agents that block telomerase biogenesis and G-
quadruplex-stabilizing molecules as telomere-disrupting agents. In the context of 
clinical trials though, only activity and immunotherapy-based drugs have been 













1.3 LINKING mTOR AND TELOMERASE THROUGH 
RAPAMYCIN  
1.3.1 Rapamycin as an inhibitor of mTOR 
 Rapamycin, a naturally occurring macrolide antibiotic was isolated from a 
strain of Streptomyces, and discovered to have antifungal and immunosuppressive 
properties by virtue of its ability to inhibit T-cell proliferation and allograft rejection 
in animals (Vezina, Kudelski et al. 1975; Martel, Klicius et al. 1977; Baeder, Sredy et 
al. 1992). It was in a yeast genetic screen for mutations conferring resistance to 
rapamycin, that the first TOR proteins were identified (Heitman, Movva et al. 1991).  
Rapamycin forms a complex with cytoplasmic receptor protein and 
intracellular cofactor FK506-binding protein 12 (FKBP12) and directly binds to and 
inhibits TOR proteins through an allosteric site N-terminal to its kinase domain. 
Called the FKBP12-rapamycin binding (FRB) domain, this conserved domain resides 
outside the catalytic domain and is unique to mTOR (Brown, Albers et al. 1994; Chiu, 
Katz et al. 1994; Sabatini, Erdjument-Bromage et al. 1994; Sabers, Martin et al. 
1995). This allosteric inhibition of mTOR kinase activity by rapamycin is essentially 
irreversible because the dissociation rate of binding of the FKBP12-rapamycin from 
mTOR is low (Edinger, Linardic et al. 2003). This has clinical implications because 
administration of these drugs is expected to yield a considerably more sustained 
inhibition of mTORC1 signaling than would be predicted by plasma drug 
concentrations (Chiang and Abraham 2007).  
Because activating mutations in PI3K drive a wide variety of cancers, and 
mTORC1 lies downstream of PI3K, rapamycin became one of the most sought after 
anticancer agents (Samuels, Wang et al. 2004). This was augmented by rapamycin‟s 
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specificity and potency towards mTORC1 (Feldman and Shokat 2010). Results from 
both preclinical and clinical studies of rapamycin over the past two decades have 
shown that rapamycin elicits a cytostatic response at the G1 phase of the cell cycle in 
eukaryotic cells, ranging from yeast to human (Menon and Manning 2008). This, in 
part explains why rapamycin treatment in the clinic leads to cells in the tumour 
becoming smaller without significant effect on tumour volume (Easton and Houghton 
2006; Faivre, Kroemer et al. 2006). Consequently, currently rapamycin has only been 
approved for the treatment of renal cell carcinoma and lacks broad efficacy as a 
cancer therapeutic (Feldman and Shokat 2010). This can be explained, at least in part, 
to the inability of rapamycin to target mTORC2, and also to the feedback loops that 
lead to Akt activation in response to rapamycin. This can additionally be attributable 
to rapamycin‟s poor aqueous solubility and chemical stability (Guertin and Sabatini 
2007). The development of rapamycin analogues such as CCI-779, RAD001 and 
AP23573 has kept the momentum of mTOR antagonists in anticancer research, as 
they exhibit favorable pharmaceutical properties. These agents have shown growth 
inhibitory properties against various cancer types in preclinical studies and are 
currently being evaluated against many cancers in clinical trials, with promising 
results (Mita, Mita et al. 2003).  
The observation that mTORC2 is resistant to rapamycin, at least in the short 
term, can be explained by the fact that when mTOR is in the Rictor complex, the FRB 
domain is inaccessible to the FKBP12-rapamycin complex. However, prolonged 
rapamycin treatment may affect mTORC2 by interfering with mTORC2 assembly 
resulting from rapamycin-induced sequestration of mTOR in mTORC1. In fact 
approximately 20% of tumor cell lines exhibited a decrease in mTORC2 activity 
during chronic exposure to rapamycin (Sarbassov, Ali et al. 2006). Since mTORC2 
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phosphorylates Akt at one (S473) of two sites required for full Akt activation, which 
in turn enhances overall cell survival, it is desirable from a therapeutic point of view 
to inhibit mTORC2 as well (Alessi, Andjelkovic et al. 1996). Furthermore, Akt has 
been shown to be activated by mTORC1 inhibitors such as rapamycin. This is 
explained by the fact that S6K1 delivers a negative feedback signal by 
phosphorylating insulin receptor substrate 1 (IRS-1), preventing IRS-1 from recruiting 
PI3K to the receptor for activation (Ozes, Akca et al. 2001; Tremblay, Brule et al. 
2007). Rapamycin inhibition of mTORC1 leading to inhibition of S6K1, blocks this 
feedback loop, leading to increased PI3K/AKT activation. Since several survival 
pathways are controlled downstream of PI3K/AKT, this attenuates the therapeutic 
benefit of rapamycin-induced mTORC1 inhibition. Indeed, Akt activation by 
rapamycin has been observed in tumour biopsies from clinical trials as well (O'Reilly, 
Rojo et al. 2006; Cloughesy, Yoshimoto et al. 2008; Tabernero, Rojo et al. 2008). 
Furthermore, recent evidence suggests that such rapamycin-dependent feedback 
mechanisms may involve other RTK-dependent signaling pathways too (Zhang, 
Bajraszewski et al. 2007). 
These feedback mechanisms motivated the development of active site 
inhibitors of mTOR that target both mTORC1 and mTORC2. This new generation of 
mTOR inhibitors is commonly referred to as second generation mTOR inhibitors, or 
TORKinibs because they target the active site of mTOR (Feldman and Shokat 2010). 
However, in spite of their more complete inhibition of mTOR function, they are 
reversible, ATP competitive inhibitors with shorter durations of action (Feldman, 
Apsel et al. 2009; Garcia-Martinez, Moran et al. 2009; Thoreen, Kang et al. 2009; Yu, 
Toral-Barza et al. 2009). Hence, their potency and efficacy in the clinic remains to be 
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seen. In addition, combination therapies of agents that block both mTOR and PI3K or 
mTOR and RTKs are also being explored (Guertin and Sabatini 2009).  
 
1.3.2 The mTOR-telomerase connection via rapamycin 
  While rapamycin is being tested in clinical trials, preclinical studies of 
rapamycin are yielding new and interesting mechanisms of action of this drug, outside 
of its action on mTOR. Noteworthy of these are the handful of studies that have 
reported that rapamycin inhibited telomerase in endometrial, cervical, ovarian and 
leukemia cancer cell lines as well as in normal killer cells, either by downregulating 
hTERT mRNA levels or telomerase enzymatic activity. Indeed, these studies suggest 
that downregulation of hTERT mRNA or telomerase activity may be a useful 
surrogate biomarker for assessing the anti-tumour activity of rapamycin. (Zhou, 
Gehrig et al. 2003; Kawauchi, Ihjima et al. 2005; Bae-Jump, Zhou et al. 2006; Zhao, 
Zhou et al. 2008; Bae-Jump, Zhou et al. 2010; Shafer, Zhou et al. 2010).  
Although the mechanism of action of rapamycin on telomerase is yet to be 
elucidated, there are a number of speculations that exist to explain the relationship 
between rapamycin and telomerase as well as mTOR and telomerase: one of which 
can be explained by rapamycin‟s effect on the cell cycle, another via transcriptional 
regulation and last but not the least, via the relationship between Akt and telomerase.  
In a very early study by Buchkovich and Greider, telomerase was shown to be 
regulated in the G1 phase as normal human T cells enter the cell cycle. They further 
showed that rapamycin blocked telomerase induction through an immunosuppressive 
mechanism (Buchkovich and Greider 1996). Several studies after that have shown 
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that rapamycin arrests cells at the G1 phase, and this in part, can explain why 
telomerase is blocked by rapamycin because if hTERT transcription is cell cycle 
dependent, then the effect of rapamycin on hTERT expression could be the indirect 
consequence of cell cycle arrest. Furthermore, studies have shown that the cell cycle 
protein p27 suppresses hTERT, while others have shown that rapamycin upregulates 
p27, which reinforces the idea that hTERT is modulated in a cell cycle dependent way 
in response to rapamycin (Lee, Kim et al. 2005; Zhao, Zhou et al. 2008). However, 
telomerase inhibition by rapamycin has been found to be independent of rapamycin‟s 
action on the cell cycle in some cancer cells (Zhou, Gehrig et al. 2003; Bae-Jump, 
Zhou et al. 2006; Bae-Jump, Zhou et al. 2010). In addition to these controversial 
results, the cell-cycle dependent regulation of telomerase itself remains unresolved 
(Zhu, Kumar et al. 1996; Holt, Aisner et al. 1997).  
The mTOR signaling pathway may modulate transcription of the hTERT gene. 
Interestingly, c-myc is a transcriptional modulator of hTERT, and is also downstream 
to the mTOR pathway via Akt and 4E-BP1 (Wang, Xie et al. 1998; Gera, Mellinghoff 
et al. 2004; Di Cosimo and Baselga 2008). mTOR inhibition by rapamycin leading to 
reduced levels of 4E-BP1 needed for translation of c-myc may hence result in 
decreased transcription of the hTERT gene. Further, mTORC1 inhibition by 
rapamycin modulates transcription factors such as HIF-1α, which in turn regulates the 
hTERT promoter (Hudson, Liu et al. 2002; Kyo, Takakura et al. 2008).  
 Akt has been found to phosphorylate the reverse transcriptase subunit of 
telomerase, leading to enhanced telomerase activity (Kang, Kwon et al. 1999). While 
prolonged rapamycin treatment has been shown to reduce mTORC2 levels 
(Sarbassov, Ali et al. 2006), and Akt is a direct downstream target of mTORC2 
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(Sarbassov, Guertin et al. 2005), prolonged rapamycin may diminish telomerase 
activity via Akt.    
   
1.3.3 The convergence of the mTOR pathway with telomeres and telomerase   
 In light of the above speculations regarding the link between mTOR and 
telomerase, recent evidence is indeed beginning to unravel novel mechanisms that 
associate mTOR with telomeres and telomerase, especially in the context of ageing.   
 In yeast, TOR inhibition prevented cell death in both a telomere dysfunction 
model and a telomerase mutant model, suggesting that the TOR pathway is 
specifically involved in the regulation of cell death induced by telomere dysfunction 
(Qi, Chen et al. 2008). TOR inhibition has been found to extend lifespan from 
unicellular organisms to mammals (Zoncu, Efeyan et al. 2011).  Further, an age-
dependent increase in mTORC1 activity was detected in mouse hematopoietic stem 
cells (Chen, Liu et al. 2009).  
Because telomeres are intimately linked with ageing, it is possible that 
telomeres, telomerase and TOR all function in concert in the context of critical 
physiological processes such as cancer and ageing. Consequently, rapamycin may be 
a useful tool to study the dual inhibition of mTOR and telomerase, which will enable 






1.4 BREAST CANCER AS A MODEL OF STUDY 
Breast cancer is a heterogeneous disease with various genetic and molecular 
alterations driving its growth, survival as well as response to therapy. It is currently 
broadly classified under three major subtypes based on the pattern of expression of 
hormone receptors (HR), ER and/or progesterone receptor (PR) and HER2: luminal 
tumours which are HR positive and HER2 negative, HER2 amplified tumours, and 
triple-negative breast cancers which lack expression of all three receptors (Perou, 
Sorlie et al. 2000; Di Cosimo and Baselga 2010).  
In addition to or driven by the aberrations of the aforementioned receptors, it 
is worth exploring how the mTOR pathway and telomerase drive breast 
tumourigenesis and progression.  
 
1.4.1 mTOR in breast cancer 
There is growing evidence to indicate that the PI3K/Akt/mTOR pathway is 
aberrantly regulated both genetically and epigenetically in, and contributes to the 
initiation and progression of breast cancer. In support of this, activating mutations in 
PI3K have been found to be frequently present in HR-positive and HER2-positive 
tumours (Hennessy, Smith et al. 2005; Lin, Hsieh et al. 2005; Stemke-Hale, 
Gonzalez-Angulo et al. 2008). The PI3K/Akt/mTOR pathway may also be driven by 
IGF-R and Ras, which are mutated in a majority of breast cancers (Mita, Mita et al. 
2003). Other aberrations in the PI3K/Akt/mTOR pathway commonly detected in 
breast cancers include PTEN deletions, alterations in PDK-1 and dysregulation of a 
host of downstream kinases including AKT, mTOR itself, p70S6K, S6, 4E-BP1, 
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eIF4G and Stat3 (Liaw, Marsh et al. 1997; Bachman, Argani et al. 2004; Lin, Hsieh et 
al. 2005; Di Cosimo and Baselga 2008).   
Phosphorylated forms of Akt, mTOR and 4EBP-1 increased with breast cancer 
progression from benign to more malignant forms (Zhou, Tan et al. 2004). In both 
preclinical and clinical studies of breast cancers, mTOR pathway hyperactivation has 
also been implicated in poor prognosis, survival, and resistance to other forms of 
therapy such as chemotherapy, targeted therapies and radiation (Mills, Lu et al. 2001; 
Knuefermann, Lu et al. 2003; Nagata, Lan et al. 2004; Zhou, Tan et al. 2004; Tsutsui, 
Inoue et al. 2005; Hynes and Boulay 2006; Johnston 2006; Crane, Panner et al. 2009; 
No, Choi et al. 2009; Ferte, Andre et al. 2010). For instance, patients with invasive 
breast cancers overexpressing mTOR have three times greater risk of recurrence and 
shorter disease-free survival (Bose, Chandran et al. 2006). Furthermore, the 
PI3K/Akt/mTOR pathway is currently also considered a useful biomarker for both 
early stage and metastatic breast cancers (Ferte, Andre et al. 2010).  
 
1.4.2 Telomerase in breast cancer 
 Up to 90% of all breast cancers express activation of telomerase enzyme, and 
there is a progressive increase in the mean telomerase levels with the severity of 
histopathological change (Shay and Bacchetti 1997; Carey, Hedican et al. 1998; 
Yashima, Milchgrub et al. 1998; Bieche, Nogues et al. 2000; Herbert, Wright et al. 
2001). Interestingly, comparative analyses of premalignant and malignant lesions in 
the human breast have highlighted the importance of transient telomere deﬁciency and 
subsequent telomerase activation in driving tumour progression: Premalignant lesions 
did not express signiﬁcant levels of telomerase, exhibited telomere shortening and 
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nonclonal chromosomal aberrations, while clinically apparent carcinomas displayed 
upregulated telomerase expression, longer telomeres and the ﬁxation of the abnormal 
karyotypes that may have been acquired after telomere failure and before the 
acquisition of telomerase activity (Chin, de Solorzano et al. 2004; Raynaud, 
Hernandez et al. 2010). Additionally, higher telomerase activity has been associated 
with diagnosis, and poorer prognosis and survival of breast cancer patients (Clark, 
Osborne et al. 1997; Mokbel, Parris et al. 2000; Hiyama and Hiyama 2004).   
 
1.4.3 Rapamycin in breast cancer 
 Rapamycin has been used in various preclinical models of breast cancers. 
Noteworthy of these are the studies that show that rapamycin sensitized otherwise 
poorly responsive breast cancer cells to standard chemotherapeutic agents such as 
paclitaxel, carboplatin, vinorelbine and tamoxifen (deGraffenried, Friedrichs et al. 
2004; Mondesire, Jian et al. 2004).  
Since different breast cancer cells show varied sensitivities towards 
rapamycin, several studies have sought to explore the factors that determine 
rapamycin sensitivity. As we have already seen, activation of the PI3K/Akt/mTOR 
pathway in breast cancers mostly occurs via HER2, ER, IGF and lack of PTEN, and 
some or all of these may be factors that sensitize breast cancer cells to rapamycin and 
its analogues (Chan 2004; Mondesire, Jian et al. 2004; Zhou, Tan et al. 2004). 
Overexpression of S6K1 and p-Akt are also proposed to be predictors of rapamycin 
sensitivity, while changes in cyclin D1 levels may provide a potential 
pharmacodynamic marker of response to rapamycin in breast cancer cells (Noh, 
Mondesire et al. 2004). Interestingly, rapamycin alone, or in combination with other 
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therapies may be beneficial in the prevention of breast cancer or breast cancer 
recurrence, which was supported by the evidence that premalignant breast cancer cells 
were more responsive to rapamycin than tumour cells (Kim, Zukowski et al. 2009).  
Although rapamycin itself is not being explored vigorously in the context of 
breast cancer clinical trials, its analogues (rapalogs) and TORKinibs are showing 
some promising results in breast cancer phase II trials in combination with other 
chemotherapeutic agents (Baselga, Semiglazov et al. 2009; Zhang, Duan et al. 2011). 
Furthermore, rapalogs have been shown to confer sensitivity to breast cancers that 
were otherwise resistant to common chemotherapeutic agents (Nahta and O'Regan 












1.5 OBJECTIVES, HYPOTHESIS AND SIGNIFICANCE OF 
STUDY 
The literature explored thus far highlights the relevance and importance of the 
mTOR pathway and telomerase in initiating, regulating and driving cancer 
phenotypes, including those of breast cancer. It also shows that there is limited 
efficacy of rapamycin as an anticancer agent in both preclinical and clinical contexts, 
with varied and inconclusive results in breast cancers.  
Broadly speaking, the questions that remain unanswered include, but are not 
restricted to the following: While there clearly seems to be a crosstalk between mTOR 
and telomerase in carcinogenesis and progression, what is the mechanism? Also, 
while rapamycin has been shown to act against telomerase and telomeres in some 
cancer types, can it do the same in breast cancers? 
In seeking to explore whether rapamycin can function as a dual inhibitor of the 
mTOR pathway and telomerase in breast cancer cells, and yield enhanced anticancer 
therapeutic efficacy, the objectives of the study are to: 
1. Validate breast cancer cells as a model to study the dual inhibition of mTOR 
and telomerase. 
2. Investigate rapamycin‟s inhibition of the mTOR pathway and telomerase in 
breast cancer cells and elucidate the short term effects of this inhibition. 
3. Study the effect of long term treatment of a clinically relevant dose of 
rapamycin on the mTOR pathway and telomerase in breast cancer cells.  
The investigation thus seeks to establish rapamycin not only as a dual inhibitor 
of mTOR and telomerase, but also as a tool to study the combined inhibition of 
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mTOR and telomerase. In doing so, the study finally seeks to explore whether the 
combined inhibition of both these critical anticancer targets yields enhanced 
therapeutic efficacy of breast cancers. Additionally, the study hopes to unravel novel 
mechanisms by which cancer cells may regulate the complex mTOR circuitry and 
telomerase by as yet uncharacterised mechanisms.  
Findings from the study will shed light on the mechanisms of action of 





















2.1 CELLS AND CELL CULTURE 
 Two human mammary epithelial carcinoma cells (MCF-7 and MDA-MB-231) 
were obtained from American Type Culture Collection (ATCC, Rockville, MD, 
U.S.A.). MCF-7 and MDA-MB-231 cells were maintained in Roswell Park Memorial 
Institute (RPMI)-1640 (Gibco, U.S.A.) supplemented with 10% fetal bovine serum 
(FBS; Gibco, U.S.A.), 100 U/mL penicillin/streptomycin (NUMI, Singapore). These 
two cell types were used in all the studies and formed the breast cancer model.  
 In order to elucidate endogenous levels of mTOR pathway proteins and 
telomerase in breast cancer cells in comparison to normal or non-transformed cells, 
five other cell types were used. SK-BR-3, another breast cancer cell type was 
purchased from ATCC and cultured in the same way as the other two breast cancer 
cells. MCF-10A (Clontech, U.S.A.), immortalised normal breast epithelial cell line 
was cultured in Complete Mammary Epithelial Growth Medium (MEGM; Clonetics) 
supplemented with 10% FBS and 100 U/mL penicillin/streptomycin. IMR-90 (Coriell 
Cell Repository, U.S.A.), primary human diploid fibroblasts, were cultured in Minimal 
Essential Medium (MEM; Gibco, U.S.A.), supplemented with 15% FBS, 100 U/mL 
penicillin/streptomycin, 1% vitamins (NUMI, Singapore), 2% essential and 1% non-
essential amino acids (NUMI, Singapore). TERT-BJ (Clontech), telomerase 
immortalised foreskin fibroblasts, were cultured in Dulbecco‟s Modified Eagle‟s 
Medium (DMEM; NUMI, Singapore), supplemented with 10% FBS, 100 U/mL 
penicillin/streptomycin, 18% Medium 199 (Sigma, U.S.A.), 1% sodium pyruvate 
(NUMI, Singapore) and 2% L-glutamine (NUMI, NUS). ). MRC-5-hTERT cells were 
generously provided by Dr. Hidetoshi Tahara, Hiroshima University, Hiroshima, 
Japan and were cultured in DMEM, supplemented with 10% FBS and 100 U/mL 
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penicillin/streptomycin. HeLa (ATCC), a human cervical cancer cell type was 
cultured in the same way as the breast cancer cells and was used as a control.  






2.2 MOLECULAR CHARACTERISATION OF BREAST CANCER 
CELLS 
 All cells were grown in T75 flasks (Nunc, Germany) and harvested when 75% 
confluent for western blot and TRAP, as outlined in 2.4.2 and 2.4.3, respectively.  
 
2.3 DRUG AND DRUG TREATMENT CONDITIONS 
Rapamycin (Sigma, U.S.A.) was dissolved in dimethyl sulfoxide (DMSO; 
Sigma, U.S.A.) into a stock solution of 1 mM or 10 mM.  
For short term studies, the stock of 1 mM rapamycin was diluted one thousand 
times in complete RPMI-1640 to obtain a drug concentration of 1 µM.  
For short term dose-response studies, the stock of 1 mM or 10 mM rapamycin 
was diluted one thousand times in complete RPMI-1640 to obtain a drug 
concentration of 1 or 10 µM, respectively. Subsequently, the following doses were 
obtained via serial dilution: 0.1, 0.01, 0.001 µM.  
34 
 
For long term studies, the stock of 1 mM rapamycin was diluted one thousand 
times in complete RPMI-1640 to obtain a drug concentration of 1 µM. Subsequently, 
the final concentration of 0.001 µM was obtained by serial dilution.  
 
2.4 SHORT TERM STUDIES 
2.4.1 Cell treatment  
For all western blots and cell cycle studies, MCF-7 and MDA-MB-231 cells 
were plated at a density of 500,000 cells per tissue culture dish (BD Falcon, U.S.A.) 
and 24 hours later, were treated with 1 µM rapamycin for 2, 24 and 48 hours. Cells 
were then harvested for western blot or cell cycle as outlined in 2.4.2 and 2.4.4 
respectively.  
For Telomerase Repeat Amplification Protocol (TRAP) and Single cell gel 
electrophoresis (Comet) assay, MCF-7 and MDA-MB-231 cells were plated at a 
density of 100,000 cells per 6-well plate (NUMI, Singapore) and 24 hours later, were 
treated with 1 µM rapamycin for 2, 24 and 48 hours and with rapamycin dosage 
increments (0.001 – 1 µM), respectively. Cells were then harvested as outlined in 
2.4.3 (TRAP) and 2.4.5 (Comet). 
For cytotoxic assays, cancer cells were plated in triplicates at a density of 2000 
cells/well of a 96-well plate (NUMI, Singapore); normal cells were plated in 
triplicates at a density of 5000 cells/well of a 96-well plate. Following 24 hours, cells 
were treated with rapamycin (0.001 – 10 µM) for 48 hours. Subsequently, a viability 
assay (MTT or Cell-Titer Glo) was carried out as outlined in 2.4.6.1 (MTT) and 
2.4.6.2 (Cell-Titer Glo).  
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2.4.2 Protein expression studies by western blot 
Protein Extraction and Quantification 
At the end of treatment, media was aspirated, cells were washed in ice cold 1 
× phosphate buffered saline (PBS; NUMI, Singapore), and harvested by scraping. 
Harvested pellets were then washed once in 1 mL ice cold 1 × PBS and centrifuged at 
16,100 g at 4
o
C for 5 minutes.  Total cellular protein was then extracted by lysing 
cells in lysis buffer (50 mM Tris-HCl (pH 8), 5 mM EDTA, 150 mM NaCl (NUMI, 
Singapore), 0.5% NP-40, 0.5 mM DTT, 1 × PhosSTOP, 1 × Protease cocktail 
inhibitor), following which the lysates were rotated in a rotor at 4
o
C for 1 hour. 
Subsequently, lysates were centrifuged at 16,100 g at 4
o
C for 30 minutes. 
Supernatants were transferred into fresh tubes and quantified using the Bradford 
assay.   
Western Blotting  
Equal amounts of protein (60 - 80 μg) were loaded on 5%, 10% or 12.5% 
SDS-Polyacrylamide gels, depending on molecular weight of proteins being probed 
for, and then electro-blotted onto a nitrocellulose membrane (BioRad, U.S.A.). 
Transfer of proteins was checked by Ponceau Reagent (0.5% Ponceau stain, 1% 
glacial acetic acid (Sigma, U.S.A.)). Membranes were then blocked for 60 minutes 
with 5% non-fat milk in TBS-T (0.1% Tween-20 (Sigma, U.S.A.) in 1 X TBS (0.1 M 
NaCl, 0.01 M Tris-HCl (pH 7.4))). Subsequently, membranes were probed with 
primary antibodies against target proteins overnight at 4°C, with a dilution factor of 
1:1000, unless otherwise stated. Rabbit monoclonal antibodies used were 
phosphorylated-mTOR, phosphorylated-p70S6K1, p70S6K1, phosphorylated-Akt, 
Akt (Cell Signaling, U.S.A.), and hTERT (Epitomics, Inc., U.S.A). Rabbit polyclonal 
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antibodies used were mTOR and Cyclin D1 (1:300) and mouse monoclonal antibody 
used was p21 (1:500). Goat polyclonal antibody was used for Beta-Actin (1:2000) and 
incubated at room temperature for an hour. The primary antibodies against 
phosphorylated proteins were diluted in Bovine Serum Albumin (BSA; NUMI, 
Singapore), while the rest except p21 were diluted in 5% non-fat milk in TBS-T; the 
primary antibody against p21 was diluted in TBS-T. The membranes were then 
washed thrice in TBS-T, for five minutes each to remove excess or non-specific 
binding of antibodies. Washed membranes were then incubated in goat anti-rabbit IgG 
(H+L)-HRP, goat anti-mouse IgG (H+L)-HRP or donkey anti-goat IgG (H+L)-HRP 
secondary antibodies, all diluted at 1:5000, for one hour at room temperature. (All 
antibodies were purchased from Santa Cruz Biotechnology, U.S.A. unless otherwise 
stated). Membranes were once again washed thrice in TBS-T for 5 minutes each to 
remove excess or non-specific binding of antibodies. The protein bands were 
visualized in SuperSignal West Femto (Thermo Scientific, Singapore) followed by 
exposure to X-ray film (Pierce, U.S.A.).  
Protein bands were then quantified using Kodak Molecular Imaging Software 
(Carestream Molecular Imaging; U.S.A.). All protein band intensities were then 
expressed as a ratio against their corresponding actin band intensity.  
All protein expression studies by western blot, including those done for long 






2.4.3 Telomerase activity measurement by Telomerase Repeat Amplification 
Protocol (TRAP) 
Media was aspirated out of the 6-well plates containing treated and untreated 
cells. Following washing once with 2 mL of 1 × PBS, cells were trypsinised and 
pelleted by centrifugation at 260 g for 5 minutes.  
The TRAP assay was performed using the TRAPeze XL Telomerase 
Detection Kit (Chemicon, Millipore) to measure levels of telomerase activity. This 
was carried out by lysing every 10
6
 cells in 200 uL of CHAPS lysis buffer as per 
manufacturer‟s instructions. After 60-minute incubation on ice, the lysates were 
centrifuged at 4
o
C at 12,000 g for 20 minutes and their protein concentration 
determined by the Bradford assay.  
 The reaction mixture for telomerase extension and polymerase chain reaction 
(PCR) amplification step was prepared by adding 10 uL of the 5X TRAPEZE XL 
Reaction Mix, 0.4 uL of the Taq Polymerase (5 units/µL), 37.6 µL of PCR-grade 
water and 2 µL of the cell extract containing 1.5 µg of protein into PCR tubes. The 
samples were then loaded onto a thermal cycler where telomerase elongation of the 
TS primer present in the 5X TRAPEZE XL Reaction Mix was allowed to proceed at 
30
o
C for 30 minutes before the PCR amplification by Taq Polymerase using the TS 
and RP Amplifluor primers in the 5X TRAPEZE XL Reaction Mix for 36 cycles of 
94
o
C for 30 seconds, 59
o
C for 30 seconds and 72
o
C for one minute. The reaction was 
later terminated at 72
o
C for three minutes and 55
o
C for 25 minutes and the amplified 
products stored at 4
o
C.  
 The yield of the PCR reaction was then measured by adding 50 uL of the 
sample to 150 uL of a buffer containing 10 nM Tris-HCl (pH 7.4), 0.15 M NaCl and 2 
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mM MgCl2 into each well of a flat-bottomed black 96-well plate. The resulting 
fluorescence was then read using a spectrofluorometer (TECAN) using an excitation 
filter of 485 nm and an emission filter of 535 nm for fluorescein and an excitation 
filter of 585 nm and an emission filter of 635 nm for sulforhodamine.  
 TRAP assay was carried out in the same manner for cell pellets obtained from 
long term studies as well.  
 
2.4.4 Cell Cycle profiling by Propidium Iodide (PI)-assisted Fluorescence 
Associated Cell Sorting (FACS) 
 The study of cell cycle kinetics is based on the premise that cells with 
damaged DNA will undergo cell cycle arrest at the G1 (growth 1), S (DNA synthesis) 
or G2/M (growth 2/mitosis) phases or undergo cell death if damage is beyond repair 
for the cells (Enoch and Norbury 1995). 
 Cells were harvested in the same way as for TRAP assay. Harvested cells were 
washed once in 1 × PBS, centrifuged at 260 g and fixed in 3:1 70% ethanol:1 × PBS 
to permeabilise cells to PI. Fixed samples were then washed once in 1 × PBS, 
centrifuged at 260 g and then stained with PI (Sigma): RNase A (Roche, U.S.A.) 
solution (2 mg PI and 40 mg RNaseA/100 mL 0.1% Triton X (Biorad) in 1 × PBS) 
for 30 minutes at 37
o
C in the dark. The amount of PI that a cell takes up correlates to 
the stage of the cell cycle the cell is in. RNase A removes interfering RNA that can be 
stained by PI.  
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 Samples were analysed by flow cytometry at 488 nm excitation and 610 nm 
emission. Approximately 10,000 events were collected. Data obtained was analysed 
using Summit 4.3 software.  
 
2.4.5 DNA damage analysis by alkaline single cell gel electrophoresis (Comet) 
assay 
 The Comet assay works by the principle that when DNA is damaged, it 
migrates under the influence of an electric field, and the extent of this migration can 
be quantified and represented as a measure of DNA damage (Collins 2004).   
Cells were harvested in the same way as for TRAP assay. Harvested cells were 
resuspended in Hank‟s Balanced Salt Solution (Sigma), adjusted for cell densities, and 
mixed with 0.7% low melting point agarose (Conda, Spain) before being applied onto 
Comet slides (Trevigen, U.S.A.). The subsequent steps were then carried out in the 
dark. Following solidification of the agarose at 4
o
C, slides were subjected to lysis (2.5 
M NaCl, 0.1 M EDTA (pH 8), 10 mM Tris base, 1% Triton-X) at 4
o
C for 1 hour. The 
slides were then loaded into a gel electrophoresis tank in 0.3 M NaOH, 1 mM EDTA 
(pH 13), allowed to denature for 40 minutes and run at constant 25 V/300 mA for 20 
minutes. Samples were neutralised with 0.5 M Tris-HCl (pH 7.5) for 15 minutes, 
dehydrated in 70% ethanol, and dried at 37
o
C. DNA was stained with 1:10,000 SYBR 
Green (Trevigen) in Tris-EDTA buffer. Fifty randomly selected cells per sample were 
examined under an Axioplan 2 imaging fluorescence microscope and analysed using 
Comet imager software (Metasystems, Germany). Extent of DNA damage was 
expressed as a measure of comet tail moments, which corresponds to the fraction of 
DNA in the comet tail.  
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2.4.6 Cell Viability 
2.4.6.1 MTT 
The MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) 
(Sigma) assay is based on the principle that damaged or dead cells are unable to 
metabolise as efficiently as viable cells. The tetrazolium salt, MTT, is reduced to a 
water insoluble coloured formazan only by metabolically active cells. The relative 
number of viable cells can be measured following the solubilisation and quantification 
of the formazan salt.  
A solution of 4 mg/mL of MTT was prepared and kept in the dark on ice. At 
the end of 48 hours rapamycin treatment, media was aspirated from the 96-well plate, 
following which 50 µL of the MTT solution with 50 µL of RPMI were added into 
each well and mixed well. The plate was incubated in the dark for two hours at 37
o
C. 
Subsequently, the MTT with media solution was carefully aspirated and the resulting 
formazan crystals were resuspended well in 200 µL of DMSO. Cell viability was then 
determined by absorbance at 570 nm using the µQuant Microplate 
Spectrophotometer. The results were then normalized to the readings obtained by 
DMSO treatment alone.  
2.4.6.2 CellTiter-Glo  
 The CellTiter-Glo (Promega, Singapore) Luminescent Cell Viability Assay 
determines the number of viable cells in culture based on quantitation of the ATP 
present, an indicator of metabolically active cells. The CellTiter-Glo reagent causes 
cell lysis and generates a "glow-type" luminescent signal proportional to the amount 
of ATP present, which is in turn directly proportional to the number of cells present. 
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The relative number of viable cells present can then be quantified via a luminescence 
plate reader.  
At the end of 48 hours rapamycin treatment, media was aspirated from the 96-
well plate, following which 100 µL of the CellTiter-Glo reagent with 100 µL of 
complete RPMI-1640 medium was added into each well and mixed well. The plate 
was then incubated in the dark for 10 minutes. Subsequently, the contents of the plate 
were transferred into a white-bottomed 96-well plate (Greiner), and cell viability was 
determined by quantifying the luminescence generated via an ELISA plate reader. 
The results were then normalized to the readings obtained by DMSO treatment alone.  
 
2.5 LONG TERM STUDIES 
2.5.1 Cell Treatment 
 For all long term studies, cells were plated at a density of 100,000 cells into 
each of two T75 flasks. The following day, complete media was added into one flask 
and complete media containing 0.001 µM rapamycin was added into the other flask. 
Subsequently, media was changed every two days. At the end of the first, second and 
third week of treatment, control and treated cells were harvested, counted by the 
trypan blue dye exclusion assay (2.5.2), and 100,000 cells were plated back into fresh 
T75 flasks. At the end of the first and third week of treatment, harvested cells were 
frozen at -80
o
C for use either in western blot, TRAP or Telomere Restriction 





2.5.2 Population doubling via Trypan blue dye exclusion assay 
  The assay works by the principle that the trypan blue dye is able to 
permeabilise the cell membrane of only a dead cell, staining it blue in colour. Viable 
cells with intact cell membranes hence remain impermeable to the dye, and are 
counted using a haemocytometer.  
 Population doubling number (PDN) was calculated using the formula: 
PDN = log2(Number of cells harvested/number of cells originally plated). 
 Cumulative PDN was then calculated and represented in figures.  
 
2.5.3 Telomere length measurement by Telomere Restriction Fragment (TRF) 
analysis 
 DNA Extraction 
Total DNA was extracted using DNeasy Tissue Kit (Qiagen) at room 
temperature. Pelleted cells were resuspended in 200 µL 1 × PBS. Thereafter, 200 µL 
AL Buffer and 20 µL Proteinase K were added to lyse the cells and remove proteins. 
The mixture was vortexed and incubated at 70
o
C for 10 minutes, followed by the 
addition of 200 µL ethanol. The mixture was vortexed and applied to DNeasy Mini 
Spin Column for adsorption of DNA to the column membrane. Washes with AW1 





TRF using TeloTAGGG Telomere Length Assay kit (Roche) 
2 µg of genomic DNA were digested with HinfI and RsaI restriction enzymes 
at 37
o
C for 2 hours to cut non-telomeric DNA into low molecular weight fragments, 
leaving only the sub-telomeric and telomeric DNA uncut. Digested DNA was 
resolved on a 0.8% agarose gel at 60 V. The gel was then prepared for southern 
blotting by first submerging in 0.25 M HCl, followed by denaturation in 0.5 M 
NaOH/3 M NaCl and neutralisation in 0.5 M Tris-HCl/3 M NaCl. Southern blotting 
was then carried out, where DNA fragments were transferred overnight by capillary 
transfer to a positively charged nylon membrane. The blotted DNA fragments were 
then UV-cross-linked to the membrane and hybridised with digoxigenin (DIG)-
labelled probe specific for telomeric repeats, followed by incubation with anti-DIG 
conjugated with alkaline phosphatase before adding detection buffer and substrate for 
signal detection. Telomere signals were exposed to X-Ray film (Pierce), their lengths 
determined by comparing the signals to a molecular weight marker standard using 
Kodak Molecular Imaging Software (Carestream Molecular Imaging; U.S.A.). 
Decrease in telomere length was then expressed as a function of PDN to assess the 
rate of telomere shortening.  
Telomere attrition rate was calculated by dividing the average telomere length 







2.6 Statistical Analysis 
Statistical significance between data sets was assessed using two-way Anova, 




























3.1 MOLECULAR CHARACTERIZATION OF                      
BREAST CANCER CELLS 
3.1.1 Breast cancer cells MCF-7 and MDA-MB-231 exhibited concurrent 
upregulation of phosphorylated mTOR (p-mTOR) and telomerase, albeit to 
different extents 
In order to validate the use of breast cancer cells as a model to study the 
inhibition of mTOR and telomerase, the endogenous levels of p-mTOR (S2448), total 
mTOR and hTERT were determined via western blotting. Further, basal levels of 
telomerase activity were determined by the TRAP assay. Although responsiveness of 
breast cancer cells to rapamycin seemed to be determined by levels of S6K, p-Akt and 
cyclin D1 in addition to mTOR and p-mTOR (S2448) (Noh, Mondesire et al. 2004), 
we hypothesized that combined upregulation of p-mTOR and hTERT within the same 
cell type would predict responsiveness to rapamycin. This also came from studies that 
suggested that downregulation of hTERT may be a useful surrogate biomarker for 
assessing the anticancer activity of rapamycin (Zhou, Gehrig et al. 2003). The cell 
types used for western blotting were MCF-7, MDA-MB-231, SK-BR-3, MCF-10A, 
IMR-90, TERT-BJ and HeLa. The cell types used for TRAP were the same, except 
that TERT-BJ cells were replaced with MRC5-TERT. While MCF-10A cells served 
as a control for breast cancer cells, IMR-90 cells were employed as an overall normal 
cell control; TERT-BJ and MCR5-TERT cells were studied as an additional control 
cell to investigate whether p-mTOR and mTOR would be modulated in the presence 
of TERT while HeLa cells served as an overall cancer cell control.   
Elevated phosphorylation of mTOR at S2448 was observed in all the cancer 
cells: MCF-7, MDA-MB-231, SK-BR-3 and HeLa (Figure 4 and 5A). Notably, the 
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more malignant cancer cells MDA-MB-231 and HeLa exhibited comparably higher 
phosphorylation of mTOR. While MCF-10A cells exhibited lowest p-mTOR levels, it 
was interesting to note the induction of mTOR in IMR-90 and TERT-BJ cells.  
No particular trend between cancer cells versus normal cells with respect to 
expression of total mTOR protein was observed. Interestingly, the p-mTOR/mTOR 
ratio was highest in the most malignant MDA-MB-231 and HeLa cells establishing 
that these cells exhibited the highest induction of mTOR (Figure 5B). The p-
mTOR/mTOR ratio was comparable between all the other cell types. Notably, the 
ratio in IMR-90 and TERT-BJ cells was higher than that observed in MCF-7 and 
MCF-10A cells.  
hTERT levels were more or less comparable between all cancer cells (Figure 4 
and 5A). It was not surprising to note that hTERT expression was highest in TERT-BJ 
cells. Cells that have been immortalised in cell culture also exhibit upregulation of 
telomerase, as they develop the capacity for unlimited cellular proliferation; hence, it 
was no surprise that MCF-10A too exhibited an upregulation of hTERT. IMR-90, 
being primary cells, and having limited proliferative potential, did not exhibit hTERT 
protein expression.  
Similar results were obtained in the TRAP assay (Figure 6), whereby all 
cancer cells exhibited higher basal telomerase activity compared to normal cells. 
Interestingly, we noted that MCF-10A and MRC5-TERT, despite being immortalised 
with TERT transfection, exhibited lower basal telomerase activity compared to the 
cancer cells. Finally, levels of basal telomerase activity were undetectable in IMR-90 
cells, in correspondence with hTERT protein expression.  
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Taken together, breast cancer cells MCF-7, MDA-MB-231 and SK-BR-3 cells 
as well as cervical cancer cells HeLa, but not normal cells, showed concurrent 
upregulation of p-mTOR and telomerase.  
 
Figure 4. Western blot gel profiles depicting endogenous expression levels of proteins 













Figure 5. A. Protein quantification of p-mTOR (S2448), mTOR and hTERT relative to 




Figure 6. TRAP assay depicting basal telomerase activity in cancer and normal or 





















































































3.2 RAPAMYCIN CHARACTERIZATION: SHORT TERM 
STUDIES 
 Following the observation of simultaneous upregulation of p-mTOR and 
telomerase in breast cancer cells, we proceeded to explore whether this determined 
sensitivity to rapamycin. A series of experiments were carried out to elucidate the 
short term effects of rapamycin on the mTOR pathway and telomerase. Subsequently, 
the anticancer effects of rapamycin were studied using parameters including cell cycle 
response, cell viability and DNA damage.  
 
3.2.1 Rapamycin inhibited activation of mTOR pathway in MCF-7 and MDA-
MB-231 cells  
The kinetics of rapamycin on the mTOR pathway were studied by treating 
MCF-7 and MDA-MB-231 cells to a dose of 1 µM rapamycin for 2, 24 and 48 hours. 
The resulting effects on the mTOR pathway proteins were assessed via western blot.  
MCF-7 cells showed slight and marked downregulation of p-mTOR (S2448) 
at 24 and 48 hours respectively, while MDA-MB-231 cells showed p-mTOR 
downregulation at all time points (Figures 7 and 8A). Contrastingly, total mTOR 
protein levels were not noticeably modulated in both cells at all time points, indicating 
that rapamycin only inhibited the activity of mTOR but did not modulate its levels. To 
confirm these results, the ratio of p-mTOR to mTOR was calculated and the 
percentage change between control and treated cells were then represented as in figure 
8B. The observation that both control MCF-7 and MDA-MB-231 cells showed a 
gradual upregulation (2 to 24 hours), with a subsequent downregulation (24 to 48 
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hours) of p-mTOR activity with time (Figures 7 and 8A) is indicative of the 
sensitivity of the mTOR protein to serum and growth factors in the cell culture media. 
Despite there being no apparent change in the levels of p-mTOR in MCF-7 
cells following 2 hours of treatment with rapamycin, it was interesting to note that the 
levels of p-p70S6K (T389) were completely abrogated at all time points. The 
complete depletion of p-p70S6K levels in MDA-MB-231 at all time points was 
justified by significant downregulation of p-mTOR at all time points. Once again, the 
observation that total p70S6K was un-modulated in response to rapamycin in both 
cells highlighted that the mechanism of action of rapamycin is oriented towards 
depleting the levels of phosphorylated forms of mTOR and p70S6K.  
Figures 8A and 8B seemed to suggest that p-Akt (S473) was slightly 
upregulated in MCF-7 cells at 24 and 48 hours and at 24 hours in MDA-MB-231 
cells. On the other hand, p-Akt appeared to be downregulated at 48 hours in MDA-
MB-231 cells. Interestingly, the levels of p-Akt seemed to be upregulated in both 
control and treated MDA-MB-231 cells at 48 hours compared to the other timepoints 
(Figures 7 and 8).  
Taken together, our data showed that rapamycin inhibited the mTOR pathway 







Figure 7. Western blot gel profiles of mTOR pathway proteins in MCF-7 and MDA-



















Figure 8. A. Protein quantification of mTOR pathway proteins relative to actin and B. 
ratio of phosphorylated to total protein in MCF-7 and MDA-MB-231 cells in response 
to 1 µM rapamycin treatment at 2, 24 and 48 hours 
 
3.2.2 Rapamycin did not modulate hTERT protein, but inhibited telomerase 
activity in MCF-7 and MDA-MB-31 cells, albeit to different extents  
In order to ascertain whether or not at the same time points and dose, hTERT 
levels were modulated by rapamycin in MCF-7 and MDA-MB-231 cells, hTERT 
protein expression and activity were investigated by western blot and TRAP, 
respectively.  
In response to treatment with 1 µM rapamycin for 2, 24 and 48 hours, both 
MCF-7 and MDA-MB-231 did not exhibit any significant trend in hTERT protein 
modulation (Figure 9). Interestingly though, the common trend observed in both cell 





The TRAP results showed that at all time points of rapamycin treatment in 
MDA-MB-231 cells, telomerase activity was significantly downregulated, while there 
was no significant alteration of telomerase activity in MCF-7 cells except at the 48 
hour timepoint (Figure 10).  
Taken together, our data seemed to suggest that rapamycin seemed to 
significantly alter telomerase activity in MDA-MB-231 cells at all timepoints and 
only at 48 hours in MCF-7 cells, while not markedly altering hTERT protein in both 
breast cancer cells.  
 
Figure 9. A. Western blot gel profile of hTERT protein and B. quantification of 
hTERT protein relative to actin in MCF-7 and MDA-MB-231 cells in response to 1 







Figure 10. TRAP assay of MCF-7 and MDA-MB-231 cells in response to 1 µM 
rapamycin treatment at 2, 24 and 48 hours. Data are obtained from two independent 
experiments and expressed as mean + SE. * indicates significantly lower telomerase 
activity compared to timepoint-based control (p<0.05), *** indicates significantly 
lower telomerase activity compared to timepoint-based control  (p<0.001). 
 
 
3.2.3 Rapamycin induced G1 arrest in MCF-7 and MDA-MB-231 cells at 24 and 
48 hours 
 As reviewed in the introduction, both mTOR and telomerase have a role to 
play in cell cycle progression. Having shown that rapamycin inhibited both the mTOR 
pathway and telomerase activity, we sought to investigate whether this led to possible 
cytostatic effects on MCF-7 and MDA-MB-231 cells. Rapamycin‟s effect on the cell 
cycle has been widely studied in a variety of cancer cell types, at various doses. 
Results of these studies show that rapamycin is a potent G1 phase inhibitor (Menon 
and Manning 2008). In order to observe the effect of rapamycin on breast cancer cells, 
MCF-7 and MDA-MB-231 cells were treated with 1 µM rapamycin at 2, 24 and 48 
hours.  
 Results showed that indeed rapamycin led to G1 arrest at 24 and 48 hours in 




Figure 11. Cell cycle profiles of MCF-7 and MDA-MB-231 cells in response to 1 µM 
rapamycin treatment at 2, 24 and 48 hours. Data are obtained from three independent 
experiments and expressed as mean + SE. 
 
Figure 12. Histograms depicting cell cycle profiles of MCF-7 and MDA-MB-231 cells 
in response to 1 µM rapamycin treatment at 2, 24 and 48 hours (Time (h)_Rapamycin 
(µM)). R1, R2, R3 and R4 represent different phases of the cell cycle; R1: Sub G1, 





3.2.4 Rapamycin-induced G1 arrest was independent of cyclin D1 and p21 
protein expression 
 Having observed that rapamycin treatment led to G1 phase arrest in MCF-7 
and MDA-MB-231 cells, we then went on to investigate whether this arrest was 
associated with the regulation of cell cycle proteins in the G1 phase, namely cyclin 
D1 and p21. 
 Our results showed that rapamycin-induced G1 arrest was not associated with 
significant changes in the expression of cyclin D1 and p21 proteins (Figure 13). The 
quantification result further showed that although there were changes in protein 
expression, there was as such no particular trend associated with these changes.  
 
Figure 13. A. Western blot gel profiles of cell cycle proteins and B. quantification of 
cell cycle proteins relative to actin in MCF-7 and MDA-MB-231 cells in response to 1 





3.2.5 Rapamycin had limited effect on cell proliferation following 48 hours in 
MCF-7 and MDA-MB-231 cells  
 Having studied the cytostatic potential of rapamycin on MCF-7 and MDA-
MB-231 cells, we proceeded to investigate whether rapamycin elicited a cytotoxic 
effect by the MTT assay.  
 The IC50 of rapamycin in MCF-7 and MDA-MB-231 cells has been shown to 
be 0.02 µM and 10 µM, respectively (Chen, Zheng et al. 2003). Hence we studied the 
growth inhibitory properties of rapamycin between 0.001 to 10 µM. 
 Our results indicated that there was an initial dose-dependent loss of viability 
in MCF-7 cells at 0.001 µM, but no dose-dependent loss of viability at subsequent 
doses (Figure 14). Meanwhile, no significant loss of viability was observed in MDA-
MB-231 cells, except at the highest dose of 10 µM, with there also being a significant 
decrease in viability between 1 and 10 µM. Taken together, MCF-7 cells seemed to 
exhibit greater overall loss in viability than MDA-MB-231 cells, while this effect did 
not appear to be dose-dependent in nature in both cell types.  
 Perhaps longer treatment duration may have lead to greater rapamycin 
cytotoxicity in the breast cancer cells, but the time-point chosen was 48 hours since 
this was the maximum duration of treatment that had already been studied in 




Figure 14. Viability response of MCF-7 and MDA-MB-231 cells following 48 hours 
of rapamycin treatment. Data are obtained from three independent experiments and 
expressed as mean ± SE. ** indicates significantly lower viability compared to 
control cells (p<0.01), *** indicates significantly lower viability compared to control 
cells (p<0.001) and 
#
 indicates significantly lower viability compared to cells of 
preceding dose (p<0.05). 
 
3.2.6 Rapamycin had limited effect on DNA damage following 48 hours in MCF-
7 and MDA-MB-231 cells  
Rapamycin has been shown to abrogate DNA repair capacity (Chen, Ma et al. 
2010). Further, DNA damage is known to lead to either cell cycle arrest or cell death 
depending on the extent of damage inflicted (Enoch and Norbury 1995). Our 
observation that rapamycin caused G1 arrest in MCF-7 and MDA-MB-231 cells led 
us to investigate whether DNA damage was a contributing factor to this arrest. Hence 
we looked at the DNA damage levels in these cells following 48 hours of rapamycin 
dosage increments.  
 Results showed that in both MCF-7 and MDA-MB-231 cells, there was no 




Figure 15. DNA damage response of MCF-7 and MDA-MB-231 cells following 48 
hours of rapamycin treatment. Data are obtained from two independent experiments 
and expressed as mean ± SE. 
  
3.2.7 Rapamycin led to dose-dependent loss of viability in MCF-10A and IMR-90 
cells 
In order to investigate whether or not rapamycin exerted cytotoxicity on 
normal cells, we carried out viability studies in MCF-10A and IMR-90 cells using the 
CellTiter-Glo assay.  
Our results showed that MCF-10A exhibited an initial dose-dependent loss of 
viability in response to rapamycin, which levelled off with subsequent dosage 
increments (Figure 16). IMR-90 cells also exhibited a dose-dependent loss of viability 
upto a dose of 0.01 µM, but this effect too levelled off at higher doses. Altogether, it 
appeared that in MCF-10A but not IMR-90 cells, rapamycin induced greater overall 
loss in cell viability, with roughly 40% viability at the highest dose of 1 µM in MCF-






























Figure 16. Viability response of IMR-90 and MCF-10A cells following 48 hours of 
rapamycin treatment. Data are obtained from three independent experiments and 
expressed as mean ± SE. ** indicates significantly lower viability compared to 
control cells (p<0.01), *** indicates significantly lower viability compared to control 
cells (p<0.001) and 
##
 indicates significantly lower viability compared to cells of 







3.3 RAPAMYCIN THERAPEUTICS: LONG TERM STUDIES 
3.3.1 Rationale 
 Having characterised both at a functional and mechanistic level the short term 
effects of rapamycin on the breast cancer model chosen, it was imperative that as a 
preclinical study, the investigation shifted to a more therapeutic approach. For this 
purpose a number of parameters had to be taken into account: 
1. Dose of rapamycin  
2. Time period of treatment 
3. Effect of rapamycin on normal cells 
In preclinical and clinical studies of rapamycin in a variety of cancers, the 
dose of 0.001 – 0.0.1 μM rapamycin has been shown to be clinically relevant (Wang, 
Lu et al. 2008). The lower dose of 0.001 μM was chosen for the following studies to 
minimize any cytotoxic effects on normal cells.  
The time period of treatment chosen was three weeks because a. studies have 
shown that prolonged rapamycin treatment results in the inhibition of mTORC2 
assembly and of Akt (Sarbassov, Ali et al. 2006), both of which are challenges 
associated with rapamycin use, b. there is a lag phase associated with telomerase 
inhibition and clinical efficacy; time is required for cancer cells to undergo enough 
rounds of cell divisions in order to accumulate critical telomere length erosion, which 
would then trigger crisis and apoptosis (Harley 2008). and c. we hypothesized that 




 3.3.2 Chronic rapamycin treatment compromised population doubling capacity 
of MCF-7, MDA-MB-231 and MCF-10A cells, albeit to different extents 
 To start with, the population doubling capacity of cells in response to chronic 
low dose rapamycin was studied via the trypan blue dye exclusion assay. 
The results showed that over the course of three weeks, the proliferation of 
MCF-7, MDA-MB-231 and MCF-10A treated counterparts was significantly 
abrogated when compared to their corresponding controls, as measured by the 
cumulative population doubling number (PDN) (Figure 17). In fact, even at the end of 
one week of rapamycin treatment, MCF-7 and MCF-10A cells became significantly 
sensitized to the antiproliferative effects of rapamycin, while MDA-MB-231 cells 
showed significantly lower PDN only following two and three weeks of rapamycin. 
Our data seemed to suggest that MCF-10A, similar to the short term viability results, 
exhibited highest sensitivity to chronic rapamycin, as evidenced by the PDN of the 
treated cells at all weeks. Compared to MCF-10A, MCF-7 cells exhibited lower 
sensitivity to chronic rapamycin, while MDA-MB-231 cells were the most resistant to 
the chronic effects of rapamycin. Altogether, our data seemed to suggest that MCF-
10A cells exhibited greatest sensitivity to rapamycin, followed by MCF-7, while 










Figure 17. Population doubling number (PDN) of MCF-7, MDA-MB-231 and MCF-
10A cells following chronic treatment with 0.001 µM rapamycin. Data are obtained 
from four independent experiments in MCF-7 and MDA-MB-231 cells and from two 
independent experiments in MCF-10A cells, and expressed as mean ± SE. * indicates 
significantly lower cumulative PDN compared to week-based control cells (p<0.05), 
** indicates significantly lower cumulative PDN compared to week-based control 
cells (p<0.01) and *** indicates significantly lower cumulative PDN compared to 








3.3.3 Chronic rapamycin treatment inhibited the mTOR pathway in MCF-7 and 
MDA-MB-231 cells, and led to upregulation of p-Akt in MDA-MB-231 cells 
 Just as the functional workings of rapamycin in the short term were studied via 
western blot to look at p-mTOR (S2448) and p-p70S6K (T389) inhibition (Figure 7), 
these markers were investigated in the chronic low dose scenario as well.  
 Results showed that in both MCF-7 and MDA-MB-231 cells, while the p-
mTOR levels were not significantly altered after one week of treatment, there was 
significant downregulation following three weeks (Figure 18). Interestingly, while 
total mTOR protein remained unchanged in MCF-7 throughout the duration of the 
treatment, it was completely depleted in MDA-MB-231 cells at the three week time 
point, corresponding to p-mTOR downregulation. Further, p-p70S6K activity was 
completely abolished at both time points in both cells, similar to the short term 
observations (Figure 7). While p-Akt levels remained unaltered in MCF-7 cells at 
both time points, it was interesting to note the significant upregulation of p-Akt in 






Figure 18. A. Western blot gel profiles and B. quantification of mTOR pathway 
proteins relative to actin in MCF-7 and MDA-MB-231 cells following chronic 
treatment with 0.001 µM rapamycin.  
 
3.3.4 Chronic rapamycin treatment led to slight downregulation of hTERT 
protein in MCF-7 and MDA-MB-231 cells, with a slight decrease and increase in 
telomerase activity in MCF-7 and MDA-MB-231 cells, respectively 
 Next, we sought to investigate whether chronic rapamycin treatment led to 
reduction of telomerase expression and activity in MCF-7 and MDA-MB-231 cells. 
Our results showed that while hTERT protein expression was downregulated in MCF-
7 cells following three weeks of rapamycin, downregulation of hTERT was observed 





Corresponding to the decrease in hTERT protein in MCF-7 cells, the activity 
was also downregulated slightly at both one and three week timepoints (Figure 20). 
Interestingly, despite the decrease in hTERT protein in MDA-MB-231 cells at three 
weeks, the telomerase activity appeared to be slightly upregulated.  
 
Figure 19. A. Western blot gel profile of hTERT protein and B. quantification of 
hTERT protein relative to actin in MCF-7 and MDA-MB-231 cells following chronic 
treatment with 0.001 µM rapamycin. 
 
Figure 20. TRAP assay of MCF-7 and MDA-MB-231 cells following chronic 
treatment with 0.001 µM rapamycin. Data are obtained from two independent 







3.3.5 Chronic rapamycin treatment led to reduction of telomere length in MCF-7 
but not in MDA-MB-231 cells  
 Having observed changes in telomerase protein expression and activity 
following chronic low dose rapamycin in both MCF-7 and MDA-MB-231 cells, we 
sought to investigate whether this corresponded to telomere length changes. 
 Our results showed that in MCF-7 cells, the telomere length remained more or 
less unchanged after one week of rapamycin, while there was marked shortening 
following three weeks of rapamycin (Figures 21 and 22 A). In contrast, MDA-MB-
231 cells did not exhibit observable telomere length changes at both one and three 
week time points. This data corresponded with the telomerase activity data from 
Figure 20, whereby MCF-7 cells exhibited downregulation of telomerase activity 
while MDA-MB-231 cells showed upregulation of telomerase activity.  
Specifically, our data showed that prolonged rapamycin treatment sensitised 
telomeres of MCF-7 cells as length reduction was observed at the end of three weeks, 
but a similar effect was not observed in the more malignant MDA-MB-231 cells.  
 Finally, when telomere length reduction was divided by the PDN to obtain the 
telomere attrition rate, we observed that in both cell types, treated populations of cells 




Figure 21. Southern blot depicting telomere restriction fragments of MCF-7 and 














Figure 22. A. Percentage change in telomere length and B. telomere attrition rate of 
























4.1 BREAST CANCER CELLS MCF-7 AND MDA-MB-231 ARE A 
GOOD MODEL TO STUDY THE INHIBITION OF MTOR AND 
TELOMERASE 
 As reviewed earlier on in the introduction, the predictors of rapamycin 
sensitivity remain unclear. A study showed that overexpression of p-p70S6K and p-
Akt predicts rapamcyin sensitivity in a panel of breast cancer cells (Noh, Mondesire et 
al. 2004), and another study showed that increased phospholipase D activity predicts 
rapamycin resistance in breast cancer cells (Chen, Zheng et al. 2003). Interestingly, 
studies that showed that rapamycin led to telomerase inhibition in some 
gynaecological malignancies speculated that this effect could be used as an additional 
surrogate biomarker for the anticancer effects of rapamycin (Zhou, Gehrig et al. 2003; 
Kawauchi, Ihjima et al. 2005; Bae-Jump, Zhou et al. 2006; Zhao, Zhou et al. 2008; 
Bae-Jump, Zhou et al. 2010; Shafer, Zhou et al. 2010). We hence sought to 
investigate whether a concurrent upregulation of p-mTOR and telomerase could also 
be used to predict rapamycin sensitivity in breast cancer. 
In order to establish the breast cancer model MCF-7 and MDA-MB-231 cells 
as good candidates for the study of mTOR and telomerase inhibition, it was 
imperative to know the basal levels of mTOR and telomerase. Elevated activation of 
mTOR and the catalytic subunit of telomerase, hTERT, simultaneously in MCF-7 and 
MDA-MB-231 cells would suggest not only that they are good candidates to study the 
inhibition of mTOR and telomerase, respectively, but would also predict the 
responsiveness of these cells to rapamycin.   
 Our results showing elevated mTOR phosphorylation in breast cancer cells 
MCF-7, MDA-MB-231 and SK-BR-3 correlates with other studies (Figure 4); in 
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particular, the higher p-mTOR levels and p-mTOR/mTOR ratio in the metastatic 
MDA-MB-231 cells compared to the non-invasive MCF-7 and SK-BR-3 cells is in 
line with previous studies that have shown that elevated phosphorylation of mTOR 
may be associated with invasive breast tumours (Lin, Hsieh et al. 2005). Lack of 
elevated phosphorylation of mTOR in the non-cancerous MCF-10A cells not only 
correlates with other studies (Holz and Blenis 2005; Lin, Hsieh et al. 2005), but also 
implicates mTOR phosphorylation in the breast cancer phenotype.  
 It was interesting to note mTOR phosphorylation as well as higher p-
mTOR/mTOR ratio in IMR-90 and TERT-BJ cells, compared to MCF-7 and SK-BR-
3 cells. mTOR phosphorylation is governed by the presence of growth factors and 
amino acids in the culture medium (Wang, Fonseca et al. 2008; Dennis, Baum et al. 
2011); hence it is likely that at the time of harvesting the cells from culture, the levels 
of amino acids in the culture medium were sufficient to induce phosphorylation of 
mTOR in these cells. It would hence have been useful to study the un-induced levels 
of p-mTOR in all the cell types to truly assess the endogenous levels of mTOR 
phosphorylation.  
 As reviewed in the introduction, the telomerase enzyme is well established as 
an attractive anticancer target, by virtue of it being relatively universal, critical and 
also specific to cancer cells in comparison to normal cells (Harley 2008). In our 
studies, levels of telomerase in the different cell types were measured both by 
studying its protein expression and by determining basal activity (Figures 4, 5A and 
6).  
Our results that hTERT was detected in all the cancer cells and also in the 
immortalised cells, but not in primary cells reflects the criticality of the hTERT 
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enzyme in conferring cells the ability to proliferate indefinitely in culture. It was 
interesting to note that despite the relatively comparable levels of hTERT protein 
expression between all three breast cancer cells, there seemed to be differences in the 
levels of enzymatic activity, suggesting that in determining endogenous telomerase 
levels, both expression and activity may need to be investigated. Importantly, the 
higher telomerase activity in breast cancer cells compared to normal and non-
transformed cells suggested that these cells may be useful to investigate the functional 
effects of telomerase inhibition by rapamycin.  
Taken together, our data that breast cancer cells exhibited concurrent 
upregulation of both p-mTOR and hTERT led us to hypothesize that these cells would 












4.2 UPREGULATION OF p-MTOR AND TELOMERASE DOES 
NOT NECESSARILY PREDICT RESPONSIVENESS TO 
RAPAMYCIN 
The literature for the response of different cancers to rapamycin in preclinical 
in vitro studies is vast – not only is there a variety of ranges of rapamycin doses used, 
there are different effects observed at different concentrations of rapamycin (Foster 
and Toschi 2009). The literature for breast cancer cells and rapamycin generally 
indicates that at a time point of between 24 to 72 hours and at a range of doses from 
0.0001 to 10 µM, there are significant anticancer effects such as suppression of cell 
proliferation and inhibition of mTOR pathway via suppression of p70S6K activity 
(Yu, Toral-Barza et al. 2001; Chen, Zheng et al. 2003; Chen, Rodrik et al. 2005; 
Foster and Toschi 2009). 
 Keeping this data in mind, we sought to investigate the kinetics of rapamycin 
in breast cancer cells MCF-7 and MDA-MB-231 at 2, 24 and 48 hours and at a 
relatively high dose of 1 µM. We assessed this by western blotting for total and 
phosphorylated levels of the major mTOR pathway proteins: mTOR, p70S6K and 
Akt. 
 Our observation that p-mTOR (S2448) was downregulated at 24 and 48 hours 
in MCF-7 cells and at all timepoints in MDA-MB-231 cells seemed to suggest that 
MDA-MB-231 cells were more responsive to mTOR inhibition by rapamycin. 
Further, the data that total mTOR protein remained unmodulated in response to 
rapamycin, highlighted rapamycin‟s mechanism of action – at a dose of 1 µM, 
rapamycin did not affect the expression of mTOR protein, but inhibited only its 
functionally active form.  
76 
 
The time-dependent trend in p-mTOR levels in control MCF-7 and MDA-MB-
231 cells could once again be attributed to the cumulative activation of the mTOR 
pathway in response to growth factors and amino acids in the serum.  
 Most importantly, our kinetics data suggested that rapamycin inhibited 
mTORC1 and not mTORC2. This comes from two observations: 1. p-p70S6K (T389) 
was completely undetectable at all time points despite the presence of p-mTOR. It is 
well established that p70S6K is phosphorylated at T389 by mTORC1 (Kim, 
Sarbassov et al. 2002; Holz, Ballif et al. 2005) and that rapamycin inhibits the kinase 
activity of mTORC1 and not mTORC2 (Jacinto, Loewith et al. 2004; Sarbassov, Ali 
et al. 2004). Furthermore, the p-mTOR antibody employed in the studies probed for 
S2448, which is found in both mTORC1 and mTORC2 (Rosner, Siegel et al. 2010). 
Hence it can be deduced that in both MCF-7 and MDA-MB-231 cells, rapamycin may 
have completely inhibited mTORC1 at all time points, but not mTORC2, which 
explains the undetectable levels of p-p70S6K despite p-mTOR levels at all time 
points. 2. p-Akt (S473) was upregulated slightly at 24 and 48 hours in MCF-7 cells 
and at 48 hours in MDA-MB-231 cells. It is well established that mTORC2 
phosphorylates Akt at S473, leading to its full activation (Sarbassov, Guertin et al. 
2005). The observation that p-Akt and p-Akt/Akt ratio seemed to be increased in 
certain time-points in MCF-7 and MDA-MB-231 cells further suggested that 
rapamycin did not affect mTORC2.  
Un-modulated total p70S6K levels once again highlights the mechanism of 
action of rapamycin as an agent that modulates the kinase activation of the mTOR 
pathway without affecting the levels of the total protein in the pathway.  
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 As reviewed in the introduction, rapamycin has been shown to cause 
downregulation of telomerase activity and telomerase mRNA levels in some cancer 
cell types (Zhou, Gehrig et al. 2003; Kawauchi, Ihjima et al. 2005; Bae-Jump, Zhou et 
al. 2006; Bu, Jia et al. 2007; Zhao, Zhou et al. 2008; Bae-Jump, Zhou et al. 2010), 
although the mechanism is not very well understood. Our observation that rapamycin 
inhibited telomerase enzyme activity in MCF-7 and MDA-MB-231 cells, without 
altering the protein level in both cell types, suggested that rapamycin may not directly 
be affecting the expression or translation of the protein, but may directly or indirectly 
affect its enzymatic function.  
p70S6K is an upstream modulator of critical cell cycle progression proteins 
such as cyclin D1 and c-myc (Gera, Mellinghoff et al. 2004), and hTERT is 
implicated in cell cycle progression (Buchkovich and Greider 1996). Therefore our 
observation that rapamycin targeted both p70S6K activation and hTERT activity (at 
least in MDA-MB-231 cells), led us to hypothesize that rapamycin would affect cell 
cycle progression in our breast cancer model.  Further, rapamycin has been shown to 
be cytostatic at the G1 phase in a wide variety of cancers (Menon and Manning 2008).  
Indeed, we observed G1 phase arrest in both cell types at 24 and 48 hours, 
while there was no significant alteration in expression of cell cycle proteins cyclin D1 
and p21. Cyclin D1 is required for the transition of cells from the G1 to the S phase of 
the cell cycle (Fu, Wang et al. 2004); p21  is  a  direct  downstream  target  of  p53  
and  has  been  shown  to  integrate DNA damage into growth arrest and apoptotic 
signaling pathways, which ultimately determines cell  fate (Weinberg and Denning 
2002). Interestingly, our data seemed to suggest that rapamycin-induced inhibition of 
p-mTOR, p-p70S6K and telomerase activity may be correlated with induction of G1 
arrest, but that this may be independent of cyclin D1 and p21 protein expression. 
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While the majority of literature cites rapamycin‟s inhibitory effects on cyclin D1 both 
at an mRNA and protein level (Grewe, Gansauge et al. 1999; Marderosian, Sharma et 
al. 2006; Nagata, Takahashi et al. 2010), our opposing result is supported by results 
that have also shown that inhibition of mTOR and p70S6K by rapamycin is not the 
principle mechanism for the suppression of cyclin D1 (Takuwa, Fukui et al. 1999). 
Furthermore, it has been suggested that only rapamycin-sensitive but not rapamycin-
resistant cell types exhibit cyclin D1 downregulation in response to rapamycin, and 
that this effect could potentially be used as a pharmacodynmic marker of response to 
rapamycin (Noh, Mondesire et al. 2004).  
In our investigations of other anticancer functions of rapamycin, we sought to 
study the cell growth-inhibitory and DNA damage properties of rapamycin. Our 
results that rapamycin did not exert significant dose-dependent loss of cell 
proliferation or significant DNA damage in MCF-7 and MDA-MB-231 cells 
suggested that rapamycin may exert its anticancer effects in a more cytostatic rather 
than an apoptotic or cytotoxic manner in these breast cancer cells. Indeed, rapamycin 
seems to exert apoptotic effects only in a small subset of tumours, and remains 
cytostatic in most (Hosoi, Dilling et al. 1999; Huang, Liu et al. 2001). This is 
confirmed by preclinical and clinical studies whereby rapamycin leads to cells in the 
tumour becoming smaller without significant effect on tumour volume (Easton and 
Houghton 2006; Faivre, Kroemer et al. 2006). Interestingly, our viability data showed 
that MCF-10A cells were more sensitive overall to the cell growth inhibitory 
properties of rapamycin than were the breast cancer cells. A similar result was 
obtained in a study that showed that rapamycin-induced inhibition of cell proliferation 
and cell cycle was most effective in benign and premalignant breast epithelial cells as 
compared to breast cancer cells (Kim, Zukowski et al. 2009). Most importantly, our 
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data on cell proliferation in MCF-7, MDA-MB-231 and MCF-10A cells seemed to 
suggest that concurrent upregulation of p-mTOR and hTERT may not be effective 
predictors of rapamycin sensitivity; further, inhibition of the mTOR pathway and 
telomerase by rapamycin also may not necessarily translate to an anticancer effect 
such as apoptosis, although it may yield more cytostatic effects. There are several 
studies that reinforce this observation (Noh, Mondesire et al. 2004), suggesting that 
cancer cells may upregulate numerous compensatory survival pathways, or that 
cancer cells may not necessarily depend on the mTOR pathway and telomerase alone 
for survival and proliferation. Hence, although the mTOR pathway and telomerase are 
activated in most tumors, they may not be obligatory for continued cell cycle 
progression, proliferation and survival, and these processes may be mediated by 
alternative, rapamycin-insensitive pathways. 
Our motivation to investigate rapamycin‟s effect on DNA damage came from 
two sources. Upon DNA damage, cells undergo replicative arrest if the damage is 
repairable and undergo apoptosis if the DNA damage inflicted is beyond repair 
(Enoch and Norbury 1995). Hence, our observation of cell cycle arrest led us to 
speculate that this could be a consequence of DNA damage. This speculation was 
strengthened by a recent study that showed that mTOR inhibition by rapamycin 
suppressed repair of DNA double strand breaks, implicating rapamycin in DNA 
damage and repair (Chen, Ma et al. 2010). However, our results seemed to indicate 
that at the dose and time-point of rapamycin used, rapamycin did not seem to exert 





4.3 CHRONIC LOW DOSE RAPAMYCIN TREATMENT IN 
BREAST CANCER CELLS REVEALS A NOVEL MECHANISM 
OF RAPAMYCIN RESISTANCE INVOLVING AKT AND 
TELOMERASE 
 Our long term PDN data that MCF-10A cells showed the highest 
responsiveness to rapamycin compared to the breast cancer cells reinforced the 
possibility that high levels of active mTOR and hTERT do not necessarily predict 
responsiveness to rapamycin. Hence, our data seemed to suggest that both short term 
and a therapeutic dose of rapamycin elicit a similar response in terms of cell 
proliferation. Furthermore, similar to the short term results, the observation that MCF-
7 cells were more sensitive to rapamycin than MDA-MB-231 cells suggested that 
rapamycin may be more effective in inhibiting the proliferation of less malignant cell 
types. Importantly, the observation that even treated cells continued to proliferate, 
albeit at a lower rate, suggested that these cells may be employing compensatory 
survival and proliferative pathways.  
 Interestingly, the reduction in PDN did not seem to correspond to a 
proportionate reduction in the mTOR pathway in both MCF-7 and MDA-MB-231 
cells. While MDA-MB-231 cells exhibited higher resistance to inhibition in cell 
proliferation, the western blot data showed that these cells displayed higher reduction 
in both p-mTOR (S2448) and mTOR levels compared to MCF-7 cells. The complete 
depletion of mTOR in MDA-MB-231 cells seemed to suggest that prolonged 
rapamycin treatment in these cells may have led to reduction in rapamycin-insensitive 
mTORC2 as well, as previously shown by Sarbassov and colleagues (Sarbassov, Ali 
et al. 2006). This has far reaching implications, because mTORC2 has recently been 
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shown to be involved in promoting invasion and metastasis via activation of Akt 
(Kim, Yun et al. 2011). Taken together, results from PDN and mTOR pathway 
seemed to suggest that a reduction in mTOR may not necessarily be associated with 
an anticancer effect. Importantly, the depletion of p-p70S6K (T389) in both cells 
highlighted this discrepancy, while also corresponding with short term data.  
 Contrastingly, the observation of elevated p-Akt (S473) in MDA-MB-231 
cells, but not MCF-7 cells seemed to be associated with the PDN result of lower 
responsiveness in MDA-MB-231 cells. Because total mTOR was abrogated in MDA-
MB-231 cells following three weeks of rapamycin, the activated Akt may have arisen 
from the abrogation of the classic feedback loop that exists between S6K and IRS-1, 
leading to enhanced proliferation in these cells (Ozes, Akca et al. 2001; Tremblay, 
Brule et al. 2007). Interestingly, the fact that we did not observe p-Akt upregulation in 
short term data seemed to suggest that chronic, but not acute rapamycin treatment 
leading to mTOR and p70S6K inhibition leads to accumulation of activated Akt, 
while why this effect seemed to be cell-type dependent remains to be elucidated.  
 Chronic rapamycin at a therapeutic dose led to responses very different from 
those observed in short term studies, with respect to telomerase. While short term 
rapamycin treatment did not lead to marked alterations in hTERT protein levels, long 
term treatment led to downregulation of hTERT protein in both cell types, with there 
being a marked decrease in MCF-7 cells at three weeks. MCF-7 cells also exhibited 
inhibition in telomerase activity at both time points, with there being greater 
inhibition at three weeks. These data corresponded with the telomere length reduction 
and telomere attrition rate observed in MCF-7 cells at three weeks. The significant 
inhibition of PDN in MCF-7 cells at three weeks could hence possibly be associated 
with a decrease in the mTOR pathway as well as hTERT at the same time point.  
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Interestingly, in spite of the slight downregulation of hTERT protein in MDA-
MB-231 cells in response to rapamycin, we observed an upregulation in the activity. 
This could possibly explain the lack of apparent telomere length reduction between 
week 1 and week 3 rapamycin-treated MDA-MB-231 cells. It is hence possible that a 
relatively lower responsiveness of MDA-MB-231 cells to rapamycin (in terms of 
PDN) was associated with a concomitant elevation in p-Akt and hTERT activity, and 
also a lack of significant decrease in telomere length.  
As reviewed in the introduction, Akt has been proposed to be a link between 
the mTOR pathway and telomerase, because hTERT is a known substrate of Akt 
(Kang, Kwon et al. 1999). Hence, it is possible that prolonged rapamycin treatment 
leading to activated Akt could lead to enhanced hTERT activity via this mechanism in 
MDA-MB-231 cells.  
While it has been suggested that one of the mechanisms of rapamycin 
resistance in cancers occurs via the upregulation of the prosurvival Akt via feedback 
mechanisms, we hypothesize that a possible consequence of Akt activation leading to 
rapamycin resistance may involve enhanced telomerase activity. Once again, why this 
appears to be cell-type dependent remains to be elucidated. However, it is interesting 
to note the difference that therapeutic rapamycin elicits in benign versus malignant 
tumours. Our data seems to suggest that one possible mode of rapamycin resistance, 
occurring in response to prolonged rapamycin in more malignant tumours may occur 
via enhanced telomerase activity as a result of elevated p-Akt. Indeed, both elevated 
Akt and telomerase have been associated with enhanced invasion and metastasis 
(Herbert, Wright et al. 2001; Kim, Yun et al. 2011). Finally, our data implicates Akt 
in the mechanism of action of rapamycin on telomerase.  
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The speculated relationship between the mTOR complexes, Akt, telomerase 
and rapamycin as observed in the long term studies is depicted in the working model 
in Figure 23.  
 
Figure 23. Working model of mTOR pathway-telomerase-rapamycin interaction in 
control and chronic low dose rapamycin treated MCF-7 and MDA-MB-231 cells. In 
control cells, IRS-1 stimulates PI3K which in turn phosphorylates and activates Akt. 
Akt is also phosphorylated and activated by mTORC2. Active Akt signals to its 
downstream effector mTORC1, which in turn activates S6K. S6K functions in a 
negative feedback loop to IRS-1, which shuts down signalling in the pathway. Akt has 
also recently been implicated in the activation of telomerase, while another possible 
link between the mTOR pathway and telomerase is via c-myc which is activated by 
S6K. In chronic low dose rapamycin treated MCF-7 cells, mTORC1 may be inhibited, 
subsequently leading to inhibition of S6K (not shown in figure). While this shuts down 
the negative feedback loop to IRS-1 leading to enhanced Akt, and subsequently 
increased telomerase, rapamycin may also be inhibiting telomerase activity. This may 
lead to telomere attrition and reduced cell proliferation. In chronic low dose 
rapamycin treated MDA-MB-231 cells, both mTORC1 and mTORC2 may be 
inhibited. This shuts down the negative feedback loop to IRS-1, which continues to 
phosphorylate and activate PI3K to produce more of Akt. Overstimulation of Akt may 
lead to enhanced activation of telomerase, and hence continued cell proliferation. 


















5.1 CONCLUSIONS AND SIGNIFICANCE 
Taken together, both our short term and long term data seem to suggest that 
while breast cancer cells may be a useful model to study the effects of inhibiting the 
mTOR pathway and telomerase, the activation of these two players alone cannot 
predict the responsiveness of these cells to rapamycin. Furthermore, it appears that 
rapamycin-induced inhibition of the mTOR pathway and telomerase does not 
necessarily translate to a reduction in viability of cells, but rather imposes a more 
cytostatic effect. This is in correspondence with the vast majority of literature that 
cites rapamycin predominantly as a G1 cytostatic agent rather than one that induces 
apoptosis (Easton and Houghton 2006; Faivre, Kroemer et al. 2006; Menon and 
Manning 2008). Our results further show that the cytostatic effect elicited by 
rapamycin on breast cancer cells may be independent of the expression of critical cell 
cycle proteins such as cyclin D1 and p21, and of damage inflicted on DNA.  
Importantly, our data implicates novel mechanisms other than mTOR, 
specifically telomerase, in mediating the anticancer effects of rapamycin; this shows 
that rapamycin may not be eliciting its effects through the inhibition of mTOR and 
p70S6K alone. Finally, findings from this study show that while short term rapamycin 
treatment may function as a dual inhibitor of mTOR and telomerase, sustained 
rapamycin treatment leading to Akt activation may play a role in resistance via 
telomerase activation in some breast cancers, possibly the more malignant forms.  
Altogether, the investigation highlights a novel mode of rapamycin action and 
shows that rapamycin may be a useful tool to study the molecular network linking 




5.2 FUTURE DIRECTIONS 
The long term studies highlighted that resistance to rapamycin may not only 
be conferred by elevated p-Akt and possibly telomerase, but by several other 
compensatory survival pathways. This comes from the observation that despite long 
term rapamycin treatment, both MCF-7 and MDA-MB-231 cells continued to 
proliferate, albeit at a lower rate. It would hence be interesting to do a microarray on 
week 3 treated cells, to study the various genes that may have been upregulated in 
response to chronic low dose rapamycin. Following elucidation of these genes and 
their pathways, it would be useful to carry out combination strategies to inhibit such 
pathways that may be providing survival advantage and resistance to rapamycin. For 
instance, data from this investigation suggest that the combined inhibition of mTOR, 
Akt and telomerase may provide a more efficient therapeutic approach compared to 
mTOR and telomerase alone, at least in MDA-MB-231 cells. 
While the present study has sought to unravel a novel mechanism of action of 
rapamycin via its action on telomeres and telomerase, it is still unclear how mTOR 
and telomerase regulate each other. It would be interesting to silence mTOR in breast 
cancer cells and study the resulting effects on telomere/telomerase homeostasis.  
It has been shown that knockout of TERT leads to genomic instability (Liu, 
Snow et al. 2000). Similarly, rapamycin-induced inhibition of mTOR has been shown 
to lead to compromised repair of DNA double strand breaks (Chen, Ma et al. 2010). 
Hence, another combination strategy would be to carry out inhibition of mTOR in a 
TERT knockout cell line or inhibition of TERT in an mTOR silenced cell line; the 
resulting effects on genomic instability both at a whole genome level and a 
chromosomal level can be studied. The objective of such a combinatorial approach 
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would be to elucidate whether the lack of one target enhances the genomic instability 
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